WO2023013785A1 - Snareを活用した核酸構築物 - Google Patents
Snareを活用した核酸構築物 Download PDFInfo
- Publication number
- WO2023013785A1 WO2023013785A1 PCT/JP2022/030200 JP2022030200W WO2023013785A1 WO 2023013785 A1 WO2023013785 A1 WO 2023013785A1 JP 2022030200 W JP2022030200 W JP 2022030200W WO 2023013785 A1 WO2023013785 A1 WO 2023013785A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- nucleic acid
- seq
- ova
- amino acid
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 120
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 292
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 292
- 239000002157 polynucleotide Substances 0.000 claims abstract description 292
- 239000000427 antigen Substances 0.000 claims abstract description 274
- 108091007433 antigens Proteins 0.000 claims abstract description 271
- 102000036639 antigens Human genes 0.000 claims abstract description 271
- 102000000583 SNARE Proteins Human genes 0.000 claims abstract description 74
- 108010041948 SNARE Proteins Proteins 0.000 claims abstract description 74
- 230000028993 immune response Effects 0.000 claims abstract description 74
- 102100036499 Vesicle-associated membrane protein 7 Human genes 0.000 claims abstract description 39
- 101000829933 Homo sapiens Golgi SNAP receptor complex member 1 Proteins 0.000 claims abstract description 25
- 102100023324 Golgi SNAP receptor complex member 1 Human genes 0.000 claims abstract description 24
- 101000706160 Homo sapiens Syntaxin-10 Proteins 0.000 claims abstract description 23
- 101000585028 Homo sapiens Syntaxin-18 Proteins 0.000 claims abstract description 23
- 102100031099 Syntaxin-10 Human genes 0.000 claims abstract description 23
- 102100029961 Syntaxin-18 Human genes 0.000 claims abstract description 23
- 102100024013 Golgi SNAP receptor complex member 2 Human genes 0.000 claims abstract description 22
- 101000873111 Homo sapiens Vesicle transport protein SEC20 Proteins 0.000 claims abstract description 22
- 102100035030 Vesicle transport protein SEC20 Human genes 0.000 claims abstract description 20
- 101000831895 Homo sapiens Syntaxin-7 Proteins 0.000 claims abstract description 19
- 102100024174 Syntaxin-7 Human genes 0.000 claims abstract description 19
- 101000706184 Homo sapiens Syntaxin-16 Proteins 0.000 claims abstract description 17
- 101000697810 Homo sapiens Syntaxin-5 Proteins 0.000 claims abstract description 17
- 102100027973 Syntaxin-5 Human genes 0.000 claims abstract description 17
- 101000852161 Homo sapiens Vesicle-associated membrane protein 8 Proteins 0.000 claims abstract description 16
- 102100031100 Syntaxin-16 Human genes 0.000 claims abstract description 16
- 101000706152 Homo sapiens Syntaxin-12 Proteins 0.000 claims abstract description 15
- 101000648224 Homo sapiens Syntaxin-8 Proteins 0.000 claims abstract description 15
- 101000631907 Homo sapiens Vesicle-trafficking protein SEC22b Proteins 0.000 claims abstract description 15
- 102100028808 Syntaxin-8 Human genes 0.000 claims abstract description 15
- 102100036505 Vesicle-associated membrane protein 8 Human genes 0.000 claims abstract description 15
- 102100028753 Vesicle-trafficking protein SEC22b Human genes 0.000 claims abstract description 15
- 102100031117 Syntaxin-12 Human genes 0.000 claims abstract description 14
- 101000904234 Homo sapiens Golgi SNAP receptor complex member 2 Proteins 0.000 claims abstract description 3
- 101000621459 Homo sapiens Vesicle transport through interaction with t-SNAREs homolog 1A Proteins 0.000 claims abstract description 3
- 101000852166 Homo sapiens Vesicle-associated membrane protein 7 Proteins 0.000 claims abstract description 3
- 102100023019 Vesicle transport through interaction with t-SNAREs homolog 1A Human genes 0.000 claims abstract 2
- 102000039446 nucleic acids Human genes 0.000 claims description 117
- 108020004707 nucleic acids Proteins 0.000 claims description 117
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 63
- 229940023146 nucleic acid vaccine Drugs 0.000 claims description 63
- 239000013600 plasmid vector Substances 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 230000024932 T cell mediated immunity Effects 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 31
- 108020004999 messenger RNA Proteins 0.000 claims description 30
- 102000006437 Proprotein Convertases Human genes 0.000 claims description 29
- 108010044159 Proprotein Convertases Proteins 0.000 claims description 29
- 239000003623 enhancer Substances 0.000 claims description 19
- 208000023275 Autoimmune disease Diseases 0.000 claims description 18
- 239000000411 inducer Substances 0.000 claims description 16
- 239000013603 viral vector Substances 0.000 claims description 14
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000002538 fungal effect Effects 0.000 claims description 11
- 229940022399 cancer vaccine Drugs 0.000 claims description 7
- 238000009566 cancer vaccine Methods 0.000 claims description 7
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 323
- 102000004196 processed proteins & peptides Human genes 0.000 description 293
- 229920001184 polypeptide Polymers 0.000 description 272
- 150000001413 amino acids Chemical group 0.000 description 229
- 239000002773 nucleotide Substances 0.000 description 169
- 125000003729 nucleotide group Chemical group 0.000 description 169
- 230000003834 intracellular effect Effects 0.000 description 168
- 210000001808 exosome Anatomy 0.000 description 165
- 108090000623 proteins and genes Proteins 0.000 description 147
- 210000001163 endosome Anatomy 0.000 description 106
- 102000004169 proteins and genes Human genes 0.000 description 79
- 235000018102 proteins Nutrition 0.000 description 78
- 210000003412 trans-golgi network Anatomy 0.000 description 63
- 210000002288 golgi apparatus Anatomy 0.000 description 54
- 230000004927 fusion Effects 0.000 description 50
- 239000013598 vector Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 46
- 239000012634 fragment Substances 0.000 description 45
- 108090000978 Interleukin-4 Proteins 0.000 description 40
- 238000000034 method Methods 0.000 description 39
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 38
- 101710205051 Vesicle-associated membrane protein 7 Proteins 0.000 description 37
- 238000004519 manufacturing process Methods 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 28
- 210000003712 lysosome Anatomy 0.000 description 26
- 230000001868 lysosomic effect Effects 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 230000006870 function Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 125000000539 amino acid group Chemical group 0.000 description 23
- 230000002708 enhancing effect Effects 0.000 description 23
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 22
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 22
- 230000001939 inductive effect Effects 0.000 description 22
- 101710178610 Golgi SNAP receptor complex member 2 Proteins 0.000 description 21
- 230000021633 leukocyte mediated immunity Effects 0.000 description 20
- 210000004988 splenocyte Anatomy 0.000 description 20
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 19
- 238000011510 Elispot assay Methods 0.000 description 18
- 206010020751 Hypersensitivity Diseases 0.000 description 18
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 18
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 18
- -1 VTI1A Proteins 0.000 description 17
- 230000007815 allergy Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 208000026935 allergic disease Diseases 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 238000005406 washing Methods 0.000 description 14
- 208000035473 Communicable disease Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 238000004064 recycling Methods 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 241000233866 Fungi Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 239000013566 allergen Substances 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000011725 BALB/c mouse Methods 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 238000004040 coloring Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000010162 Tukey test Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000017307 interleukin-4 production Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 6
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 108700021021 mRNA Vaccine Proteins 0.000 description 6
- 229940126582 mRNA vaccine Drugs 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108010041986 DNA Vaccines Proteins 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 5
- 108060004795 Methyltransferase Proteins 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 101100077708 Mus musculus Mog gene Proteins 0.000 description 4
- 230000029662 T-helper 1 type immune response Effects 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 241000238876 Acari Species 0.000 description 3
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 3
- 241000180579 Arca Species 0.000 description 3
- 244000281762 Chenopodium ambrosioides Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 235000003484 annual ragweed Nutrition 0.000 description 3
- 235000006263 bur ragweed Nutrition 0.000 description 3
- 235000003488 common ragweed Nutrition 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003746 feather Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000046004 human WT1 Human genes 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 235000009736 ragweed Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 229940023147 viral vector vaccine Drugs 0.000 description 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 2
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000238710 Dermatophagoides Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000721578 Melopsittacus Species 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000282373 Panthera pardus Species 0.000 description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 102000046699 human CD14 Human genes 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 102100024419 28S ribosomal protein S31, mitochondrial Human genes 0.000 description 1
- 101710119973 28S ribosomal protein S31, mitochondrial Proteins 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010058060 Alanine-tRNA ligase Proteins 0.000 description 1
- 102000006268 Alanine-tRNA ligase Human genes 0.000 description 1
- 102100024401 Alpha-1D adrenergic receptor Human genes 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000208841 Ambrosia trifida Species 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 108010036280 Aquaporin 4 Proteins 0.000 description 1
- 102000004392 Aquaporin 5 Human genes 0.000 description 1
- 108090000976 Aquaporin 5 Proteins 0.000 description 1
- 102100037276 Aquaporin-4 Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000003924 Asparagine-tRNA ligases Human genes 0.000 description 1
- 108090000314 Asparagine-tRNA ligases Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000122818 Aspergillus ustus Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100021526 BPI fold-containing family A member 2 Human genes 0.000 description 1
- 101710193979 BPI fold-containing family A member 2 Proteins 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 1
- 102100032378 Carboxypeptidase E Human genes 0.000 description 1
- 108010058255 Carboxypeptidase H Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241001522864 Cryptococcus gattii VGI Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 102000008178 Cyclin B1 Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 101150095770 GOSR1 gene Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108010051724 Glycine-tRNA Ligase Proteins 0.000 description 1
- 102000019220 Glycyl-tRNA synthetases Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 240000007058 Halophila ovalis Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241001456088 Hesperocnide Species 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 102000029746 Histidine-tRNA Ligase Human genes 0.000 description 1
- 101710177011 Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 1
- 101000984710 Homo sapiens Lymphocyte-specific protein 1 Proteins 0.000 description 1
- 101001051810 Homo sapiens MORC family CW-type zinc finger protein 3 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101100041773 Homo sapiens SEC22B gene Proteins 0.000 description 1
- 101100258104 Homo sapiens STX16 gene Proteins 0.000 description 1
- 101100097000 Homo sapiens STX18 gene Proteins 0.000 description 1
- 101100422646 Homo sapiens STX5 gene Proteins 0.000 description 1
- 101100534543 Homo sapiens STX7 gene Proteins 0.000 description 1
- 101100311317 Homo sapiens STX8 gene Proteins 0.000 description 1
- 101000828633 Homo sapiens Synaptobrevin homolog YKT6 Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 1
- 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000019297 Lupus La proteins Human genes 0.000 description 1
- 108050006655 Lupus La proteins Proteins 0.000 description 1
- 102100027105 Lymphocyte-specific protein 1 Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102100024822 MORC family CW-type zinc finger protein 3 Human genes 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 102100036423 Muscarinic acetylcholine receptor M3 Human genes 0.000 description 1
- 108050008508 Muscarinic acetylcholine receptor M3 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 240000008114 Panicum miliaceum Species 0.000 description 1
- 235000007199 Panicum miliaceum Nutrition 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010004478 Phenylalanine-tRNA Ligase Proteins 0.000 description 1
- 102000002798 Phenylalanine-tRNA Ligase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710096715 Probable histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101710146427 Probable tyrosine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 102100023433 RNA-binding protein RO60 Human genes 0.000 description 1
- 101710200888 RNA-binding protein RO60 Proteins 0.000 description 1
- 101000737809 Rattus norvegicus Cadherin-related family member 5 Proteins 0.000 description 1
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 1
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 108700029450 S cerevisiae PMS1 Proteins 0.000 description 1
- 101150029520 STX10 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 108010051611 Signal Recognition Particle Proteins 0.000 description 1
- 102000013598 Signal recognition particle Human genes 0.000 description 1
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 description 1
- 101710081623 Small ubiquitin-related modifier 1 Proteins 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150003891 Stx18 gene Proteins 0.000 description 1
- 101150080829 Stx5 gene Proteins 0.000 description 1
- 101150074625 Stx7 gene Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102100023512 Synaptobrevin homolog YKT6 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000001618 Threonine-tRNA Ligase Human genes 0.000 description 1
- 108010029287 Threonine-tRNA ligase Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000018378 Tyrosine-tRNA ligase Human genes 0.000 description 1
- 101710107268 Tyrosine-tRNA ligase, mitochondrial Proteins 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 101150072409 VAMP7 gene Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 102000000072 beta-Arrestins Human genes 0.000 description 1
- 108010080367 beta-Arrestins Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 108010019521 carbonic anhydrase VI Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108091006007 citrullinated proteins Proteins 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045258 human BNIP1 Human genes 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000052692 human GOSR1 Human genes 0.000 description 1
- 102000047463 human GOSR2 Human genes 0.000 description 1
- 102000049952 human STX12 Human genes 0.000 description 1
- 102000057270 human STX16 Human genes 0.000 description 1
- 102000043269 human VAMP7 Human genes 0.000 description 1
- 102000057137 human VAMP8 Human genes 0.000 description 1
- 102000047942 human VTI1A Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a nucleic acid construct comprising a polynucleotide encoding a SNARE protein and a polynucleotide encoding an antigen.
- Vaccines are a means of preventing infection and treating diseases by administering antigens and establishing acquired immunity against them.
- live vaccines that use attenuated bacteria and viruses as vaccines, inactivated vaccines that lose their infectivity by treating them with formalin or heat, etc.
- Vaccines such as inactivated toxoids are administered mainly by subcutaneous or intramuscular injection.
- mucosal vaccines in which the site of administration is a mucous membrane, nucleic acid vaccines in which the antigen component is a nucleic acid, etc. is being developed.
- nucleic acid vaccines is rapidly progressing as a new modality that can be rapidly manufactured at low cost.
- Patent Document 1 by using a nucleic acid encoding a fusion protein in which an allergen protein (antigen) is inserted between an organelle stabilization domain and a transmembrane domain of a lysosomal associated membrane protein (LAMP), , disclose that the immune response to the antigen was enhanced. On the other hand, it has been reported that addition of an antigen to the LAMP lumen may result in a significant reduction in antigen-specific antibody production (Non-Patent Document 1).
- an allergen protein antigen
- LAMP lysosomal associated membrane protein
- Patent Document 2 discloses that the immunogenicity of an antigen is increased by using a nucleic acid encoding a fusion molecule containing an antigen, a transmembrane region, and a cytoplasmic region of a major histocompatibility complex (MHC) molecular chain. is disclosed. Patent Document 2 also mentions a fusion molecule comprising an antigen and a cytoplasmic region of a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein. No indication is given as to whether it will change.
- MHC major histocompatibility complex
- SNARE proteins are a protein family with a SNARE motif of 20-30 kDa. Many SNARE proteins are tethered on lipid bilayer membranes via their C-terminal transmembrane domains and are involved in the process of vesicle fusion to target organelles (Non-Patent Documents 2 and 3). . Membrane fusion involving SNARE proteins is involved in vesicle transport, organelle membrane morphogenesis, endocytic processes including extracellular receptor recycling, hormone secretion and synaptic neurotransmitter release in eukaryotic cells. It is essential for many important life events that are essential for cell function, such as the exocytosis process.
- SNARE protein is believed to be conserved in all eukaryotes, from unicellular Saccharomyces cerevisiae to higher animals including humans.
- SNARE proteins are further classified into four subfamilies, QA-SNARE, QB-SNARE, QC-SNARE, and R-SNARE, based on the amino acid residue characteristics of the SNARE motif.
- Each SNARE protein is localized in a specific intracellular membrane fraction (endoplasmic reticulum (ER), Golgi apparatus, endosomes, organelles such as vacuoles and lysosomes, secretory vesicles, cytoplasmic membrane, etc.) It is thought to function in the process of membrane fusion in the internal transport pathway. It is also known that SNARE proteins may be contained in exosomes.
- ER endoplasmic reticulum
- Golgi apparatus endosomes
- organelles such as vacuoles and lysosomes, secretory vesicles, cytoplasmic membrane, etc.
- Patent Document 1 JP-A-2017-79742 (Patent Document 2) National Publication of International Patent Application No. 2008-500014 (Non-Patent Document 1) Chen AC, et al. J Immunother Cancer. 2020; 8(1): e000258.
- Non-Patent Document 2 Jahn R, Scheller RH. Nat Rev Mol Cell Biol. 2006; 7(9): 631-643.
- Non-Patent Document 3 Hong W. Biochim Biophys Acta. 2005; 1744(2): 120-144.
- the present invention provides the following 1) to 4).
- An antigen-specific Th1-type immune response inducer or enhancer comprising the nucleic acid construct of 1) as an active ingredient.
- An antigen-specific cellular immune response inducer or enhancer comprising the nucleic acid construct of 1) as an active ingredient.
- a nucleic acid vaccine comprising the nucleic acid construct of 1) as an active ingredient.
- IFN ⁇ immunogenicity of mRNA encoding SNARE protein-antigen fusion polypeptides.
- the amount of IFN ⁇ produced is indicated by the number of producing cells (spot forming cells; SFC). Empty indicates transfection reagent only control, Empty (N.T.) indicates no antigen restimulation control, SNARE protein-OVA indicates mRNA encoding SNARE protein-antigen (OVA) fusion polypeptide. . IgG subclass antibody titers when a plasmid vector encoding a SNARE protein-antigen fusion polypeptide was administered to mice.
- (A) shows IgG antibody titer
- (B) shows IgG1 antibody titer
- (C) shows IgG2a antibody titer.
- Empty indicates an empty plasmid vector that does not encode an antigen (OVA)
- OVA indicates an OVA-encoding plasmid vector
- V7-OVA indicates a VAMP7-OVA fusion polypeptide-encoding plasmid vector.
- (A) shows the amount of IFN ⁇ produced
- (B) shows the amount of IL-4 produced by SFC.
- C shows the ratio of IFN ⁇ production to IL-4 production (IFN ⁇ /IL-4).
- Empty indicates an empty plasmid vector that does not encode an antigen (OVA)
- OVA indicates an OVA-encoding plasmid vector
- V7-OVA indicates a VAMP7-OVA fusion polypeptide-encoding plasmid vector.
- IgG subclass antibody titers when a plasmid vector encoding a SNARE protein-antigen fusion polypeptide was administered to mice.
- A shows the IgG antibody titer
- B the IgG1 antibody titer
- C the IgG2a antibody titer
- D the ratio of the IgG2a antibody titer to the IgG1 antibody titer (IgG2a/IgG1).
- Empty is an empty plasmid vector that does not encode an antigen (OVA)
- OVA is a plasmid vector that encodes OVA
- V7-OVA, STX10-OVA, STX18-OVA, and GOSR1-OVA are VAMP7-OVA, STX10-OVA, and STX18, respectively.
- OVA is a plasmid vector that encodes OVA
- V7-OVA, STX10-OVA, STX18-OVA, and GOSR1-OVA are VAMP7-OVA, STX10-OVA, and STX18, respectively.
- -OVA indicating a plasmid vector encoding the GOSR1-OVA fusion polypeptide.
- Antibody titer over time when a plasmid vector encoding a SNARE protein-antigen fusion polypeptide or a fusion polypeptide containing an antigen inside LAMP was administered to mice.
- A is the IgG antibody titer
- B is the IgG1 antibody titer
- C is the IgG2a antibody titer
- D is the ratio of the IgG2a antibody titer to the IgG1 antibody titer at week 5 (IgG2a/IgG1).
- Empty is an empty plasmid vector that does not encode an antigen (OVA)
- OVA is a plasmid vector that encodes OVA
- V7-OVA is a plasmid vector that encodes a VAMP7-OVA fusion polypeptide
- V7-pc-OVA is a proprotein conversion.
- a plasmid vector encoding a VAMP7-OVA fusion polypeptide containing an enzyme recognition sequence, and LAMP[OVA] indicates a plasmid vector encoding a fusion polypeptide containing OVA inside LAMP.
- Evaluation of immune responses upon administration of plasmid vectors encoding SNARE protein-antigen fusion polypeptides to mice. shows the amount of IFN ⁇ produced, and (B) shows the amount of IL-4 produced by SFC.
- C) shows the ratio of IL-4 production under antigen-stimulated conditions to non-stimulated conditions (IL-4 ratio).
- OVA is a plasmid vector that encodes OVA
- V7-OVA is a plasmid vector that encodes a VAMP7-OVA fusion polypeptide
- V7-pc-OVA is a proprotein conversion.
- a plasmid vector encoding a VAMP7-OVA fusion polypeptide containing an enzyme recognition sequence is shown. IgG subclass antibody titer when a plasmid vector encoding the SNARE protein-antigen fusion polypeptide was administered to mice.
- (A) to (D) show the results when WT1 was used as the antigen, and (E) to (H) the results when MOG 35-55 was used as the antigen.
- (A) and (E) are IgG antibody titers
- (B) and (F) are IgG1 antibody titers
- (C) and (G) are IgG2a antibody titers
- (D) and (H) are IgG1 antibody titers IgG2a antibody titer ratio (IgG2a/IgG1) is shown.
- WT1 and MOG 35-55 are plasmid vectors encoding WT1 and MOG 35-55 , respectively, V7-pc-WT1 and V7-pc- MOG 35-55 indicate plasmid vectors encoding VAMP7-proprotein convertase recognition sequence-WT1 and VAMP7-proprotein convertase recognition sequence-MOG 35-55 fusion polypeptides, respectively. Evaluation of immune responses upon administration of plasmid vectors encoding SNARE protein-antigen fusion polypeptides to mice.
- (A) to (D) show the results when WT1 was used as the antigen
- (E) to (H) the results when MOG 35-55 was used as the antigen.
- (A) and (E) show the amount of IFN ⁇ produced
- (B) and (F) show the amount of IL-4 produced by SFC.
- (C) and (G) are the ratio of IL-4 production under antigen-stimulated conditions to non-stimulated conditions (IL-4 ratio)
- (D) and (H) are IFN ⁇ production relative to IL-4 production. ratio (IFN ⁇ /IL-4).
- WT1 and MOG 35-55 are plasmid vectors that encode WT1 and MO 35-55 , respectively, V7-pc-WT1 and V7-pc- MOG 35-55 indicate plasmid vectors encoding VAMP7-proprotein convertase recognition sequence-WT1 and VAMP7-proprotein convertase recognition sequence-MOG 35-55 fusion polypeptides, respectively. Evaluation of immune responses upon administration of SNARE protein-antigen fusion polypeptides or plasmid vectors encoding fusion polypeptides containing antigens within LAMP to mice.
- A shows the amount of IFN ⁇ produced
- B shows the amount of IL-4 produced by SFC.
- C shows the ratio of IL-4 production under antigen-stimulated conditions to non-stimulated conditions (IL-4 ratio)
- D shows the ratio of IFN ⁇ production to IL-4 production (IFN ⁇ /IL-4 ).
- Empty is an empty plasmid vector that does not encode an antigen (OVA)
- OVA is a plasmid vector that encodes OVA
- V7-OVA is a plasmid vector that encodes a VAMP7-OVA fusion polypeptide
- V7-pc-OVA is a proprotein conversion.
- a plasmid vector encoding a VAMP7-OVA fusion polypeptide containing an enzyme recognition sequence, and LAMP[OVA] indicates a plasmid vector encoding a fusion polypeptide containing OVA inside LAMP.
- nucleic acid includes cDNA, genomic DNA, and synthetic DNA
- RNA includes total RNA, mRNA, rRNA, tRNA, non-coding RNA, and synthetic RNA.
- mRNA is synthesized by in vitro transcription reaction for the reasons of initiation of translation reaction in vivo, stabilization of mRNA, suppression of degradation, etc., and then addition of 5' Cap (methylated guanosine) by capping enzyme, Also, addition of poly A by Poly (A) Polymerase is performed.
- a poly A sequence may be incorporated into a template DNA used for in vitro transcription reaction.
- mRNAs to which a Cap structure or polyA is added and RNAs to which some bases are modified (for example, uridine is replaced with pseudouridine or 1-methylpseudouridine) are also included.
- the term “gene” refers to double-stranded DNA containing genomic DNA, single-stranded DNA (positive strand) containing cDNA, and single-stranded DNA (complementary strand) having a sequence complementary to the positive strand. strands), and fragments thereof, which contain some biological information in the sequence information of the bases that make up the DNA.
- the “gene” includes not only “gene” represented by a specific nucleotide sequence, but also nucleic acids encoding their homologues (i.e., homologues or orthologs), variants such as genetic polymorphisms, and derivatives. be done.
- the gene names and Gene IDs disclosed herein follow the Official Symbols and Gene IDs described in NCBI ([www.ncbi.nlm.nih.gov/]).
- peptide As used herein, the terms “peptide”, “polypeptide” or “protein” are used interchangeably.
- amino acid residue refers to 20 amino acid residues that constitute proteins, alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (GIu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L ), Lysine (Lys or K), Methionine (Met or M), Phenylalanine (Phe or F), Proline (Pro or P), Serine (Ser or S), Threonine (Thr or T), Tryptophan (Trp or W) , tyrosine (Tyr or Y) and valine (Val or V).
- nucleotide sequences or amino acid sequences is calculated by the Lipman-Pearson method (Science, 1985, 227: 1435-1441). Specifically, it is calculated by performing analysis using a homology analysis (Search homology) program of genetic information processing software Genetyx-Win with Unit size to compare (ktup) set to 2.
- search homology search homology program of genetic information processing software Genetyx-Win with Unit size to compare (ktup) set to 2.
- At least 80% identity with respect to a nucleotide sequence or amino acid sequence means 80% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably Identity of 98% or more, preferably 99% or more.
- nucleotide sequence means preferably 1 to 15, more preferably 1 to 9 , more preferably 1 to 6.
- one or several used in relation to deletion, substitution, addition or insertion of amino acid residues in an amino acid sequence means preferably 1 to 5, more preferably It can mean 1-3, more preferably 1-2.
- addition of nucleotides or amino acid residues includes addition of nucleotides or amino acid residues to one and both termini of a sequence.
- stringent conditions include the conditions described in Molecular Cloning-A Laboratory Manual Third Edition (Joseph Sambrook, David W. Russell., Cold Spring Harbor Laboratory Press, 2001), for example, Southern hybridization conditions , 6 ⁇ SSC (composition of 1 ⁇ SSC: 0.15 M sodium chloride, 0.015 M sodium citrate, pH 7.0), 0.5% SDS, 5 ⁇ Denhardt and 100 mg/mL herring sperm DNA. and incubating at 42° C. for 8 to 16 hours for hybridization.
- a "fragment" of a polynucleotide means a partial polynucleotide of the polynucleotide.
- the length of the partial polynucleotide is not particularly limited as long as it encodes a polypeptide having the same function as the polypeptide encoded by the full-length polynucleotide.
- the partial polynucleotide is preferably 30% or more, more preferably 40% or more, still more preferably 50% or more, and preferably 90% or less, more preferably 80% or less, and still more preferably can mean a polynucleotide consisting of no more than 70%, even more preferably no more than 60% of the length of contiguous nucleotides.
- a "fragment" of a polypeptide means a partial polypeptide of the polypeptide.
- the length of the partial polypeptide is not particularly limited.
- the partial polypeptide is preferably 30% or more, more preferably 40% or more, still more preferably 50% or more, and preferably 90% or less, more preferably 80% or less, and still more preferably may mean a polypeptide consisting of 70% or less, even more preferably 60% or less of the length of contiguous amino acid residues.
- a "regulatory region” is a region that has the function of regulating the expression of a gene (for example, a protein-encoding region) located downstream thereof. More specifically, a “regulatory region” can be defined as a region located upstream of the coding region of a gene and having the function of interacting with RNA polymerase to regulate transcription of the coding region.
- the control region includes a transcription initiation control region and/or a translation initiation control region, or a region from the transcription initiation control region to the translation initiation control region.
- a transcription initiation regulatory region is a region containing a promoter and a transcription initiation site
- a translation initiation regulatory region is a site corresponding to a Kozak sequence recognized by ribosomes and necessary for translation initiation together with an initiation codon.
- operably linked between a regulatory region and a polynucleotide of a gene (e.g., a polynucleotide encoding a protein) means that the gene and the regulatory region are in a state where the gene is under the control of the regulatory region. It means that they are linked so that they can be expressed. Procedures for "operably linking" genes and regulatory regions are well known to those of skill in the art.
- the term “expressible linkage” between a polynucleotide of a first gene (e.g., a polynucleotide encoding a protein) and a polynucleotide of a second gene (e.g., a polynucleotide encoding a protein) refers to When the first gene and the second gene are inserted into an appropriate expression vector and the expression vector is introduced into an appropriate cell, the protein encoded by the first gene and the second gene encode It means that two proteins are linked so that they are produced as a fusion protein.
- “ligation” is a concept that includes both cases in which the first gene and the second gene are directly linked and cases in which they are linked via another nucleotide sequence. Procedures for "expressible linking" of a first gene with a second gene are well known to those skilled in the art.
- upstream and downstream with respect to a gene or its nucleotide sequence refer to upstream and downstream in the transcription direction of the gene.
- upstream sequence and downstream sequence refer to the sequences located on the 5' and 3' sides of the gene in the DNA sense strand, respectively.
- the term "antigen” means a molecule that causes an immune response such as antibody production or cell-mediated immunity in a living body.
- the term “immunogenicity” means the property of an antigen to induce antibody production and cell-mediated immunity.
- nucleic acid vaccine refers to a vaccine that induces immunity by administering a polynucleotide (DNA or RNA) encoding an antigen to a living body.
- Nucleic acid vaccines include DNA vaccines, mRNA vaccines, and virus vector vaccines, all of which are believed to induce both humoral and cellular immunity.
- DNA vaccines contain plasmids encoding antigens. Plasmids administered to living organisms are taken up by cells and transcribed into mRNA in the nucleus, and the mRNA is translated into antigen proteins in the cytoplasm to induce antigen-specific immune responses.
- An mRNA vaccine contains the mRNA that encodes the antigen.
- Viral vector vaccines comprise apathogenic or attenuated viral vectors incorporating polynucleotides encoding antigens.
- a virus administered to a living body invades cells, causes the cells to synthesize antigen proteins, and induces an antigen-specific immune response.
- cell-mediated immunity refers to acquired immune responses that work to eliminate foreign substances such as pathogens, virus-infected cells, and cancer cells that have invaded the body, such as cytotoxic T cells, macrophages, and NK cells. refers to an immune response in which is an effector.
- cytotoxic T cells cytotoxic T cells
- macrophages macrophages
- NK cells cytotoxic T cells
- NK cells cytotoxic T cells
- NK cells refers to an immune response in which is an effector.
- Th1-type immune response refers to an immune response promoted by Th1 cells, which are a subset of helper T cells. Th1 cells mainly produce IFN ⁇ as a cytokine, target M1 macrophages, cytotoxic T cells and NK cells as main target cells, and mainly induce cell-mediated immunity. Th1 cells are known to activate B cells and induce the production of IgG2a. As used herein, the term “Th2-type immune response” refers to an immune response promoted by Th2 cells, which are a subset of helper T cells.
- Th2 cells mainly produce IL-4, IL-5, IL-13 as cytokines, mast cells, M2 macrophages, eosinophils and basophils as main target cells, and mainly induce humoral immunity. do. Th2 cells are known to activate B cells and induce the production of IgG1.
- the present invention relates to providing nucleic acid constructs that enhance antigen-specific immune responses.
- nucleic acid construct comprising a polynucleotide encoding a particular SNARE protein and a polynucleotide encoding an antigen, antigen-specific It has been found that a specific Th1-type immune response can be induced or enhanced, and an antigen-specific cellular immune response can be induced or enhanced.
- the nucleic acid construct of the present invention can induce or enhance an antigen-specific Th1-type immune response, and can induce or enhance an antigen-specific cellular immune response.
- Such nucleic acid constructs are useful as nucleic acid vaccines.
- the present invention provides a polynucleotide encoding any SNARE protein selected from the group consisting of VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5, GOSR1, STX8, STX12, VAMP8, and SEC22B. , and a polynucleotide encoding an antigen.
- a SNARE protein is a protein belonging to a protein family having a SNARE motif, specifically VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5, GOSR1, STX8, STX12, VAMP8. , and SEC22B (hereinafter sometimes simply referred to as SNARE protein).
- the SNARE protein is preferably any one selected from the group consisting of VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5, and GOSR1 from the viewpoint of immune induction or enhancement, and VAMP7, GOSR2, Any selected from the group consisting of STX10, STX18, BNIP1, STX7, VTI1A, and GOSR1 is more preferred, and any selected from the group consisting of VAMP7, GOSR2, STX10, and GOSR1 is more preferred, and VAMP7 is even more preferred. .
- the SNARE protein has a transmembrane domain and localizes to intracellular vesicles.
- VAMP7 vesicle-associated membrane protein 7
- VAMP7 is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in late endosomes, lysosomes and cell membranes.
- the VAMP7 is a mammalian VAMP7.
- VAMP7 is human VAMP7 and is a protein consisting of the amino acid sequence of SEQ ID NO: 10 encoded by the gene (Gene ID: 6845) consisting of the nucleotide sequence of SEQ ID NO: 1.
- VAMP7 used in the present invention includes VAMP7 and polypeptides having functions equivalent thereto.
- GOSR2 (golgi SNAP receptor complex member 2) is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in the endoplasmic reticulum-Golgi body intermediate interval and the Golgi body.
- the GOSR2 is mammalian GOSR2.
- GOSR2 is human GOSR2 and is a protein consisting of the amino acid sequence of SEQ ID NO: 11 encoded by the gene (Gene ID: 9570) consisting of the nucleotide sequence of SEQ ID NO: 2.
- GOSR2 used in the present invention includes GOSR2 and polypeptides having functions equivalent thereto.
- STX (syntaxin) 10 is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the trans-Golgi network.
- the STX10 is mammalian STX10.
- STX10 is human STX10, a protein consisting of the amino acid sequence of SEQ ID NO: 12 encoded by the gene (Gene ID: 8677) consisting of the nucleotide sequence of SEQ ID NO: 3.
- STX10 used in the present invention includes STX10 and polypeptides having functions equivalent thereto.
- STX18 is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in the endoplasmic reticulum.
- the STX18 is a mammalian STX18.
- STX18 is human STX18, a protein consisting of the amino acid sequence of SEQ ID NO: 13 encoded by the gene (Gene ID: 53407) consisting of the nucleotide sequence of SEQ ID NO: 4.
- STX18 used in the present invention includes STX18 and polypeptides having functions equivalent thereto.
- BNIP1 (BCL2 interacting protein 1) is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the endoplasmic reticulum.
- the BNIP1 is a mammalian BNIP1.
- BNIP1 is human BNIP1 and is a protein consisting of the amino acid sequence of SEQ ID NO: 14 encoded by the gene (Gene ID: 662) consisting of the nucleotide sequence of SEQ ID NO: 5.
- BNIP1 used in the present invention includes BNIP1 and polypeptides having functions equivalent thereto.
- STX7 is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in early and late endosomes.
- the STX7 is a mammalian STX7.
- STX7 is human STX7, a protein consisting of the amino acid sequence of SEQ ID NO: 15 encoded by the gene (Gene ID: 8417) consisting of the nucleotide sequence of SEQ ID NO: 6.
- STX7 used in the present invention includes STX7 and polypeptides having functions equivalent thereto.
- VTI1A (vesicle transport through interaction with-SNAREs 1A) is a type of SNARE protein, has a transmembrane domain, and is predicted to localize in the trans-Golgi network.
- the VTI1A is a mammalian VTI1A.
- VTI1A is human VTI1A and is a protein consisting of the amino acid sequence of SEQ ID NO: 16 encoded by the gene (Gene ID: 143187) consisting of the nucleotide sequence of SEQ ID NO: 7.
- VTI1A used in the present invention includes VTI1A and polypeptides having functions equivalent thereto.
- STX16 is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the trans-Golgi network.
- the STX16 is a mammalian STX16.
- STX16 is human STX16, a protein consisting of the amino acid sequence of SEQ ID NO: 17 encoded by the gene (Gene ID: 8675) consisting of the nucleotide sequence of SEQ ID NO: 8.
- STX16 used in the present invention includes STX16 and polypeptides having functions equivalent thereto.
- STX5 is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the Golgi apparatus.
- the STX5 is a mammalian STX5.
- STX5 is human STX5 and is a protein consisting of the amino acid sequence of SEQ ID NO: 18 encoded by the gene (Gene ID: 6811) consisting of the nucleotide sequence of SEQ ID NO: 9.
- STX5 used in the present invention includes STX5 and polypeptides having functions equivalent thereto.
- GOSR1 is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the Golgi apparatus and trans-Golgi network.
- the GOSR1 is a mammalian GOSR1.
- GOSR1 is human GOSR1 and is a protein consisting of the amino acid sequence of SEQ ID NO: 76 encoded by the gene (Gene ID: 9527) consisting of the nucleotide sequence of SEQ ID NO: 71.
- GOSR1 used in the present invention includes GOSR1 and polypeptides having functions equivalent thereto.
- STX8 is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in early endosomes, late endosomes, and cell membranes.
- the STX8 is a mammalian STX8.
- STX8 is human STX8 and is a protein consisting of the amino acid sequence of SEQ ID NO: 77 encoded by the gene (Gene ID: 9482) consisting of the nucleotide sequence of SEQ ID NO: 72.
- STX8 used in the present invention includes STX8 and polypeptides having functions equivalent thereto.
- STX12 is a type of SNARE protein, has a transmembrane domain, and is predicted to be localized in the Golgi apparatus, early endosomes and recycling endosomes.
- the STX12 is a mammalian STX12.
- STX12 is human STX12 and is a protein consisting of the amino acid sequence of SEQ ID NO: 78 encoded by the gene (Gene ID: 23673) consisting of the nucleotide sequence of SEQ ID NO: 73.
- STX12 used in the present invention includes STX12 and polypeptides having functions equivalent thereto.
- VAMP8 is a type of SNARE protein, has a transmembrane domain, and is expected to be localized in lysosomes, early endosomes, late endosomes and cell membranes.
- the VAMP8 is a mammalian VAMP8.
- VAMP8 is human VAMP8 and is a protein consisting of the amino acid sequence of SEQ ID NO: 79 encoded by the gene (Gene ID: 8673) consisting of the nucleotide sequence of SEQ ID NO: 74.
- VAMP8 used in the present invention includes VAMP8 and polypeptides having functions equivalent thereto.
- SEC22B (SEC22 homolog B, vesicle trafficking protein) is a type of SNARE protein, has a transmembrane domain, and is localized to the endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus, cis-Golgi network and trans-Golgi network. expected to exist.
- the SEC22B is a mammalian SEC22B.
- SEC22B is human SEC22B and is a protein consisting of the amino acid sequence of SEQ ID NO: 80 encoded by the gene (Gene ID: 9554) consisting of the nucleotide sequence of SEQ ID NO: 75.
- SEC22B used in the present invention includes SEC22B and polypeptides having equivalent functions.
- a polypeptide having a function equivalent to that of a SNARE protein refers to a polypeptide having biological activity equivalent to that of the SNARE protein.
- Such polypeptides include, for example, polypeptides that have a transmembrane domain and can localize to intracellular vesicles (preferably intracellular vesicles in which the corresponding SNARE proteins are localized) or exosomes. . Specific examples include the following (b) to (e), or the following (b), (c) and (e) polypeptides.
- VAMP7 include the following.
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, has a transmembrane domain, and is localized in intracellular vesicles (e.g., late endosomes or lysosomes) or exosomes a polypeptide capable of;
- (e) is a fragment of any of the polypeptides of (a) to (d) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., late endosomes or lysosomes) or exosomes
- Polypeptides that can As a splicing variant of the VAMP7 gene consisting of the nucleotide sequence of SEQ ID NO: 1, proteins registered as NM_001185183.2 or NM_001145149.3 in RefSe
- GOSR2 include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 11, and has a transmembrane domain, intracellular vesicles (e.g.
- endoplasmic reticulum-Golgi intermediate interval or Golgi or exosomes
- exosomes consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2, has a transmembrane domain, and has an intracellular vesicle (e.g., endoplasmic reticulum-Golgi intermediate interval or Golgi apparatus ) or a polypeptide capable of localizing in exosomes; (e) a fragment of any of the polypeptides of (a) to (d) above, and having a transmembrane domain, intracellular vesicles (e.g., endoplasmic reticulum-Golgi intermediate interval or Golgi apparatus) or exosomes
- STX 10 include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 12, and has a transmembrane domain, intracellular vesicles (e.g.
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 3, has a transmembrane domain, and is localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- a polypeptide capable of (e) is a fragment of any of the polypeptides of (a) to (d) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes Polypeptide.
- Splicing variants of the STX10 gene consisting of the nucleotide sequence of SEQ ID NO: 3 are registered in RefSeq of NCBI as NM_001271610.2, NM_1271609.2, or NM_001271611.2, respectively, NP_001258539.1, NP_001258538.1, or NP_0011258540.
- STX 18 include the following.
- a polypeptide consisting of the amino acid sequence of SEQ ID NO: 13 consists of an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 13, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes a polypeptide;
- c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 13, and has a transmembrane domain, intracellular vesicles (e.g.
- endoplasmic reticulum or exosomes
- exosomes consisting of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 4, having a transmembrane domain, and being localized in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes a polypeptide capable of (e) a fragment of any of the polypeptides of (a) to (d) above and having a transmembrane domain and capable of localizing in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes peptide.
- Splicing variants of the STX18 gene consisting of the nucleotide sequence of SEQ ID NO: 4 are registered in RefSeq of NCBI as NM_001346281.2, NM_001346282.2, or NM_001346300.2, respectively, NP_001333210.1, NP_001333211.1, or NP_0011332.
- BNIP1 include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 14, and has a transmembrane domain, intracellular vesicles (e.g.
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 5, and has a transmembrane domain, and is localized in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes a polypeptide capable of (e) a fragment of any of the polypeptides of (a) to (d) above and having a transmembrane domain and capable of localizing in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes peptide.
- a polypeptide capable of (e) a fragment of any of the polypeptides of (a) to (d) above and having a transmembrane domain and capable of localizing in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes peptide.
- Splicing variants of the BNIP1 gene consisting of the nucleotide sequence of SEQ ID NO: 5 are registered as NM_013980.3, NM_001205.3, or NM_013978.3 in RefSeq of NCBI, and are NP_053583.2, NP_001196.2, or NP_053581.2, respectively.
- STX7 include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 15, and has a transmembrane domain, intracellular vesicles (e.g.
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 6, has a transmembrane domain, and is localized to intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes a polypeptide that can be present; (e) is a fragment of any of the polypeptides (a) to (d) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes
- a polypeptide capable of Splicing variants of the STX7 gene consisting of the nucleotide sequence of SEQ ID NO: 6 are registered in RefSeq of NCBI as NM_001326578.2, NM_001326579.2,
- VTI1A include the following.
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 7, has a transmembrane domain, and is localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- a polypeptide capable of (e) is a fragment of any of the polypeptides of (a) to (d) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes Polypeptide.
- Splicing variants of the VTI1A gene consisting of the nucleotide sequence of SEQ ID NO: 7 are registered in RefSeq of NCBI as NM_145206.4, NM_001365711.1, NM_001365710.2, NM_001365712.1, NM_001365713.1, NM_001365714.1, or NM_812014.1. and variants encoding proteins designated as NP_660207.2, NP_001352640.1, NP_001352639.1, NP_001352641.1, NP_001352642.1, NP_001352643.1, or NP_001305134.1, respectively.
- STX 16 include the following.
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 8, has a transmembrane domain, and is localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- a polypeptide capable of (e) is a fragment of any of the polypeptides of (a) to (d) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes Polypeptide.
- Splicing variants of the STX16 gene consisting of the nucleotide sequence of SEQ ID NO: 8 are registered as NM_001134772.3, NM_1134773.3, NM_003763.6, or NM_001204868.2 in RefSeq of NCBI. NP_003754.2, or variants encoding proteins registered as NP_001191797.1.
- STX5 include the following.
- (d) consists of an amino acid sequence encoded by a splicing variant of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 9, and has a transmembrane domain, and is localized in intracellular vesicles (e.g., Golgi apparatus) or exosomes a polypeptide capable of (e) a fragment of any of the polypeptides of (a) to (d) above and having a transmembrane domain and capable of localizing in intracellular vesicles (e.g., Golgi apparatus) or exosomes peptide.
- Splicing variants of the STX5 gene consisting of the nucleotide sequence of SEQ ID NO: 9 are registered in RefSeq of NCBI as NM_001244666.3 or NM_001330294.2, and encode proteins registered as NP_001231595.1 or NP_001317223.1, respectively. variants.
- GOSR1 include the following.
- c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 76, and has a transmembrane domain, intracellular vesicles (e.g.
- STX8 include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 77, and has a transmembrane domain, intracellular vesicles (e.g.
- (e) is a fragment of any of the polypeptides of (a) to (c) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes
- STX 12 include the following.
- c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 78, and has a transmembrane domain, intracellular vesicles (e.g.
- Golgi apparatus early endosomes or recycling endosomes
- exosomes a fragment of any of the polypeptides of (a) to (c) above, and having a transmembrane domain, in intracellular vesicles (e.g., Golgi apparatus, early endosomes or recycling endosomes) or exosomes
- a polypeptide capable of localization e.g., Golgi apparatus, early endosomes or recycling endosomes
- VAMP8 include the following.
- a polypeptide consisting of the amino acid sequence of SEQ ID NO:79 consists of an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 79 and has a transmembrane domain and is localized to intracellular vesicles (e.g., lysosomes, early endosomes or late endosomes) or exosomes a polypeptide that can be present;
- c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 79, and has a transmembrane domain, intracellular vesicles (e.g.
- a polypeptide capable of a polypeptide having a transmembrane domain has a transmembrane domain, and is localized in intracellular vesicles (e.g., lysosomes, early endosomes or late endosomes) or exosomes
- SEC 22B include the following.
- (c) consists of an amino acid sequence in which one or several amino acids are deleted, substituted, added, or inserted with respect to the amino acid sequence of SEQ ID NO: 80, and has a transmembrane domain, intracellular vesicles (e.g.
- endoplasmic reticulum endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus, cis-Golgi network or trans-Golgi network
- exosomes exosomes
- a polynucleotide encoding a SNARE protein used in the present invention includes a polynucleotide encoding a SNARE protein and a polynucleotide encoding a polypeptide having a function equivalent to that of the SNARE protein.
- Specific examples of polynucleotides encoding polypeptides having functions equivalent to SNARE proteins include (g) to (k) and (m) to (o) below, or (g) and (h) below, (j), (k) and (m)-(o) polynucleotides.
- polynucleotides encoding VAMP7 include the following.
- (g) consists of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 1, has a transmembrane domain, and is localized in intracellular vesicles (e.g., late endosomes or lysosomes) or exosomes;
- a polynucleotide encoding a polypeptide capable of (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 1, and has a transmembrane domain, and intracellular vesicles (e.g.
- late endosomes or lysosomes or a polypeptide that can be localized in exosomes
- (O) is a fragment of any of the polypeptides (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., late endosomes or lysosomes) or exosomes
- polynucleotides encoding GOSR2 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 2, and has a transmembrane domain, intracellular vesicles (e.g.
- endoplasmic reticulum-Golgi intermediate interval or Golgi or a polynucleotide encoding a polypeptide capable of localizing in exosomes
- endoplasmic reticulum-Golgi intermediate interval or Golgi or a polypeptide that can be localized in exosomes;
- polynucleotides encoding STX10 include the following.
- (g) consists of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 3, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- a polynucleotide encoding a polypeptide capable of (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 3, and has a transmembrane domain, intracellular vesicles (e.g.
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- polynucleotides encoding STX18 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 4, and has a transmembrane domain, intracellular vesicles (e.g.
- polypeptide that is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes
- a polynucleotide that encodes a peptide is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., endoplasmic reticulum) or exosomes.
- polynucleotides encoding BNIP1 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 5, and has a transmembrane domain, intracellular vesicles (e.g.
- endoplasmic reticulum or exosomes, encoding a polypeptide
- polynucleotides encoding STX7 include the following.
- (g) consists of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 6 and has a transmembrane domain and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes a polynucleotide encoding a polypeptide capable of;
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 6, and has a transmembrane domain, intracellular vesicles (e.g.
- an intracellular vesicle e.g., early endosome or late endosome
- a polynucleotide encoding a polypeptide capable of localizing in exosomes is a fragment of the
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes
- polynucleotides encoding VTI1A include the following.
- a polynucleotide encoding a polypeptide capable of (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 7, and has a transmembrane domain, intracellular vesicles (e.g.
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- polynucleotides encoding STX16 include the following.
- (g) consists of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 8, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- a polynucleotide encoding a polypeptide capable of (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 8, and has a transmembrane domain, intracellular vesicles (e.g.
- (k) is a fragment of the polynucleo
- trans-Golgi network or a polypeptide capable of localizing in exosomes
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and can be localized in intracellular vesicles (e.g., trans-Golgi network) or exosomes
- polynucleotides encoding STX5 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 9, and has a transmembrane domain, intracellular vesicles (e.g.
- Golgi apparatus or a polypeptide capable of localizing to exosomes
- (O) a fragment of any of the polypeptides of (l) to (n) above and having a transmembrane domain and capable of localizing in intracellular vesicles (e.g., Golgi apparatus) or exosomes
- polynucleotides encoding GOSR1 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 71, and has a transmembrane domain, intracellular vesicles (e.g.
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., Golgi apparatus or trans-Golgi network) or exosomes
- polynucleotides encoding STX8 include the following.
- (g) consists of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 72 and has a transmembrane domain and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes a polynucleotide encoding a polypeptide capable of;
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 72, and has a transmembrane domain, intracellular vesicles (e.g.
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., early endosomes or late endosomes) or exosomes
- polynucleotides encoding STX12 include the following. (f) a polynucleotide consisting of the nucleotide sequence of SEQ ID NO:73; (g) consisting of a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO: 73 and having a transmembrane domain, an intracellular vesicle (e.g.
- a polynucleotide encoding a polypeptide capable of localizing in a (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 73, and has a transmembrane domain, intracellular vesicles (e.g.
- polynucleotides encoding VAMP8 include the following.
- (h) consists of a nucleotide sequence in which one or several nucleotides are deleted, substituted, added, or inserted with respect to the nucleotide sequence of SEQ ID NO: 74, and has a transmembrane domain, intracellular vesicles (e.g.
- lysosomes, early endosomes or late endosomes hybridizes under stringent conditions to a complementary strand of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 74, has a transmembrane domain, and contains intracellular vesicles (e.g., lysosomes, early endosomes or late a polynucleotide encoding a polypeptide capable of localizing to endosomes) or exosomes; (k) is a fragment of the polynucleotide of any of (f)-(h) and (j) above and has a transmembrane domain and is an intracellular vesicle (e.g., lysosome, early endosome or late endosome); or a polynucleotide encoding a polypeptide capable of localizing in exosomes; (l) a polynucleo
- lysosomes, early endosomes or late endosomes or a polypeptide that can be localized in exosomes
- (O) is a fragment of any of the polypeptides of (l) to (n) above, has a transmembrane domain, and is localized in intracellular vesicles (e.g., lysosomes, early endosomes, or late endosomes) or exosomes
- Polynucleotides encoding SEC22B specifically include the following.
- endoplasmic reticulum endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus, cis-Golgi network or trans-Golgi network
- a polynucleotide encoding a polypeptide capable of localizing in exosomes
- (j) hybridizes under stringent conditions to a complementary strand of a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 75, has a transmembrane domain, and has an intracellular vesicle (e.g., endoplasmic reticulum, endoplasmic reticulum- a polynucleotide encoding a polypeptide capable of localizing to the intermediate Golgi, Golgi, cis-Golgi network or trans-Golgi network) or exosomes; (k) is a fragment of the polynucleotide of any one of (f) to (h) and (j
- endoplasmic reticulum endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus, cis-Golgi network or trans-Golgi network
- polypeptide that can be localized in exosomes
- (O) is a fragment of the polypeptide of any one of (l) to (n) above, has a transmembrane domain, and contains an intracellular vesicle (e.g., endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus) , cis-Golgi network or trans-Golgi network) or a polypeptide capable of localizing to exosomes.
- intracellular vesicle e.g., endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate interval, Golgi apparatus
- cis-Golgi network or trans-Golgi network a polypeptide capable of local
- the method for obtaining the polynucleotide encoding the SNARE protein of the present invention is not particularly limited, and it can be obtained by a conventional chemical synthesis method or genetic engineering method.
- a polynucleotide encoding a SNARE protein can be artificially synthesized based on the nucleotide sequences of any of SEQ ID NOs: 1-9 and 71-75.
- a commercially available DNA synthesis service provided by GenScript, etc. can be used.
- SEQ ID NOS: 1-9 and 71-75 Any nucleotide sequence can be cloned.
- Polynucleotides encoding SNARE proteins of the present invention can also be produced by introducing mutations into DNA consisting of the nucleotide sequences of any of SEQ ID NOs: 1-9 and 71-75, for example.
- Techniques for mutagenesis include, for example, ultraviolet irradiation and site-directed mutagenesis.
- Techniques for site-directed mutagenesis include methods using Splicing overlap extension (SOE) PCR (Horton et al., Gene, 77, 61-68, 1989), ODA method (Hashimoto-Gotoh et al., Gene, 152, 271-276, 1995), Kunkel method (Kunkel, TA, Proc. Natl. Acad. Sci.
- SOE Splicing overlap extension
- polynucleotides encoding the SNARE proteins of the present invention can be obtained by selecting mutagenized DNAs that have transmembrane domains and can localize to intracellular vesicles.
- Whether or not the polypeptide encoded by the mutated DNA has a transmembrane domain can be determined, for example, by SOSUI (Hirokawa et al., Bioinformatics, 14(4)) based on the amino acid sequence of the polypeptide encoded by the DNA. :378-379, 1998), TMHMM (Krogh et al., J Mol Biol. 305(3):567-580, 2001).
- nucleotide sequences are described, for example, in Dieffenbach et al. (Cold Spring Harbor Laboratory Press, New York, 581-621, 1995).
- the polynucleotide encoding the SNARE protein of the present invention can be obtained by using artificial DNA nucleases or programmable nucleases, for example, DNA consisting of the nucleotide sequences of any one of SEQ ID NOS: 1-9 and 71-75. It can also be obtained by subjecting it to genome editing.
- Any antigen can be used in the present invention.
- Specific examples include cancer antigens, autoantigens, infectious disease antigens, allergens, and the like.
- a cancer antigen is a marker for distinguishing cancer cells from normal cells when the immune system attacks cancer, and is expressed in cancer cells but not in normal cells. It means a protein or a peptide derived from a protein that is not expressed or expressed in a small amount even if it is expressed.
- Cancer antigens include, but are not limited to, MAGEA1-4, NY-ESO-1, PRAME, SSX2, CT83, CD19, GP100, MART1, PSA, PSMA, tyrosinase, WT1, HER2, MUC1, CEA, survivin, cyclin B1, EGFR, mesothelin, telomerase, MUC1T, LSP1, BCR-ABL1, HRAS, proteins commonly found in cancer patients such as KRAS or peptides derived from them, newly generated due to gene mutation in cancer cells and neoantigens, which are cancer antigens and are considered to be highly immunogenic.
- WT1, neoantigens, or peptides derived therefrom are preferred as cancer antigens, and WT1 or peptides derived therefrom are more preferred.
- an autoantigen is a protein that induces an autoimmune reaction in a host and causes an autoimmune disease although it is originally a normal body constituent, or a peptide derived therefrom, or a specific disease cause in the host. It means a target protein or a peptide derived from it that is expected to treat a disease by artificially inducing an immune response against the antigen.
- Autoantigens that cause autoimmune diseases are not particularly limited, but for type I diabetes, for example, Carboxypeptidase H, Chromogranin A, Glutamate decarboxylase, Imogen-38, Insulin, Insulinoma antigen-2, Insulinoma antigen-2B, Islet Proteins such as specific glucose-6-phosphatase catalytic subunit related protein and proinsulin or peptides derived therefrom, and in multiple sclerosis, ⁇ -enolase, aquaporin-4, ⁇ -arrestin, Myelin basic protein, Myelin oligolytic, Proteins such as proteolipid protein and S100- ⁇ , or peptides derived therefrom, and rheumatoid arthritis include proteins such as Citrullinated protein, Collagen II, Heat shock proteins, Human cartilage glycoprotein 39, and peptides derived therefrom. ⁇ La antigen ⁇ histone proteins ⁇ Ribonucleoproteins ⁇ Phospholipid- ⁇ -2 glycoprotein I complex ⁇ Poly (A
- Myelin oligodendrotic glycoprotein or a peptide derived therefrom is preferable as the autoantigen.
- Autoantigens that serve as targets for artificially inducing an immune response include proteins such as Amyloid ⁇ and Tau protein or peptides derived therefrom in Alzheimer's disease, and proteins such as ⁇ sinuclein or such in Parkinson's disease.
- Peptides derived from arteriosclerosis include proteins such as cholesterol ester transfer protein, ApoB-100, protein convertase subtilisin/kexin type 9, and heat shock protein 60, or peptides derived therefrom.
- RNKL receptor activator of NF-kappaB ligand
- infectious disease antigens include antigens derived from infectious disease-causing viruses, bacteria, fungi and protozoa.
- a viral antigen means a protein that constitutes a virus or a peptide derived therefrom.
- Viral antigens include, but are not limited to, influenza virus, coronavirus, respiratory syncytial virus, adenovirus, poliovirus, coxsackievirus, echovirus, Japanese encephalitis virus, herpes virus, mumps virus, measles virus, rubella virus, norovirus, and rotavirus.
- a bacterial antigen means a protein that constitutes a bacterium or a peptide derived therefrom.
- Bacterial antigens include, but are not limited to, pertussis, diphtheria, Escherichia coli, Haemophilus influenzae, Helicobacter, meningococcus, pseudomonas aeruginosa, pneumococcus, group A streptococcus, group B streptococcus, Staphylococcus aureus, and tetanus. Constituent proteins of bacteria such as bacteria, Legionella, tubercle bacillus, and mycoplasma, or peptides derived therefrom.
- a fungal antigen means a protein that constitutes a fungus or its spores, or a peptide derived therefrom.
- fungal antigens include fungi of the genus Aspergillus (e.g., Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, Aspergillus nidulans, Aspergillus niger, Aspergillus ustus, etc.), fungi of the genus Blastomyces (e.g., Blastomyces dermatitidis), fungi of the genus Candida (e.g., Candida albicans, etc.). ), fungi of the genus Coccidioides (e.g. Coccidiodes immitis etc.), fungi of the genus Cryptococcus (e.g.
- Aspergillus e.g., Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, Aspergillus nidulans, Aspergillus niger, Aspergillus ustus
- a protozoan antigen means a protein that constitutes a protozoan or a peptide derived therefrom.
- Protozoan antigens include constituent proteins of protozoa such as Plasmodium, Leishmania, Cryptosporidium, Trypanosoma Gambia, Trypanosoma Rhodesia, Trypanosoma cruzi, Trichomonas, Toxoplasma, Babesia, Entamoeba histolytica, and Giardia, or peptides derived therefrom.
- bacterial antigens, fungal antigens, or protozoan antigens are preferred as infectious disease antigens.
- an allergen means a protein or a peptide derived therefrom that enters the body from the outside through inhalation, puncture, ingestion, or contact and causes a hypersensitivity reaction or an allergic reaction.
- allergens include, but are not limited to, gramineous plant pollens (reeds, giant rockagaeri, giant sparrow, daffodil, sycamore, wheat, redwort, common millet, corn sorghum, long-legged grass, ragweed, broad-leaved fescue, mulberry, etc.); weed pollen (goldenia, Stinging nettle, giant ragweed, seagrass, white dandelion, wormwood, lesser sorrel, ragweed, ragweed, daisy, pear plantain, mugwort, etc.); cedar, cypress, juniper, beech, pine, willow, etc.); Penicillium, Helminthsporium, Malassezia, Mu
- antigens include glutenin, gliadin protein, or peptides derived from gluten that constitutes gluten that causes celiac disease.
- the method for obtaining the polynucleotide encoding the antigen of the present invention is not particularly limited, and it may be obtained by a conventional chemical synthesis method or genetic engineering method in the same manner as in the case of obtaining the polynucleotide encoding the SNARE protein described above. can be done.
- a polynucleotide encoding an antigen may be a polynucleotide encoding the full-length antigen, or may be a polynucleotide encoding a partial polypeptide of the antigen as long as it functions as an antigen.
- it may be a polynucleotide in which a plurality of polynucleotides encoding one antigen are linked so that they can be continuously expressed, or a polynucleotide in which polynucleotides encoding two or more antigens are linked so that they can be expressed.
- At least one type of antigen is used in the nucleic acid construct of the present invention, and preferably 5 or less types, more preferably 3 or less types, and still more preferably 2 or less types.
- 5, 4, 3, 2 or 1 antigens may be used in the nucleic acid construct of the present invention.
- the nucleic acid construct of the present invention is a nucleic acid construct in which a polynucleotide encoding an antigen is linked downstream of a polynucleotide encoding a SNARE protein in an expressible manner, more preferably a polynucleotide encoding a SNARE protein.
- nucleic acid construct in which a polynucleotide encoding an antigen downstream is linked so as to be expressible via a polynucleotide encoding a linker and/or a polynucleotide encoding a recognition sequence for a protein convertase, and more preferably , a nucleic acid construct in which a polynucleotide encoding an antigen is expressably linked downstream of a polynucleotide encoding a SNARE protein via a polynucleotide encoding a linker and a polynucleotide encoding a proprotein convertase recognition sequence.
- the order of ligation is not particularly limited, and the proprotein convertase is downstream of the polynucleotide encoding the linker.
- a polynucleotide encoding a recognition sequence may be ligated, or a polynucleotide encoding a linker may be ligated downstream of a polynucleotide encoding a proprotein convertase recognition sequence.
- a sequence in which the proprotein convertase recognition sequence is repeated about 1 to 5 times may be linked, or a poly encoding the proprotein convertase recognition sequence sandwiched between multiple polynucleotides encoding linkers. Nucleotides may be linked.
- a polynucleotide encoding a linker and a polynucleotide encoding a proprotein convertase recognition sequence should be placed between the polynucleotide encoding the SNARE protein and the polynucleotide encoding the antigen, as long as they do not impair the expression of both. Any polynucleotide may be included.
- a linker refers to a peptide linker that connects two polypeptides.
- the linker is not particularly limited as long as it allows the SNARE protein and the antigen to function normally.
- the length of the linker is preferably 3 amino acid residues or more, more preferably 4 amino acid residues or more, still more preferably 5 amino acid residues or more, and preferably 30 amino acid residues or less, more preferably 25 amino acid residues. group or less, more preferably 20 amino acid residues or less.
- the length of the linker is preferably 3 to 30 amino acid residues, more preferably 4 to 25 amino acid residues, still more preferably 5 to 20 amino acid residues.
- Such linkers include linkers having G, GS, GGS, GGGS (SEQ ID NO:92), GGGGS (SEQ ID NO:93), EAAAK (SEQ ID NO:94), or XP as constituents.
- X indicates any amino acid residue.
- Specific examples include a linker consisting of a sequence in which each component is repeated 1 to 5 times, preferably 3 or 4 times, and a preferred specific example is a linker consisting of a sequence in which GGGGS is repeated 3 times. (SEQ ID NO: 20). If the sequence component is GGGGS, the amino acid residue S may be added before the repeat sequence, or if it is EAAAK, the amino acid residue A may be added before and after the repeat sequence.
- the proprotein convertase recognition sequence refers to an amino acid sequence recognized by proprotein convertase, which is a serine protease that converts a proprotein into a physiologically active protein or peptide in the Golgi apparatus.
- proprotein convertase which is a serine protease that converts a proprotein into a physiologically active protein or peptide in the Golgi apparatus.
- X indicates any amino acid residue.
- Proprotein convertases include furin, PC2, PC4, PC5/6, PC7, PACE4 and the like, and these enzymes commonly recognize the Arg-X-(Arg/Lys)-Arg motif well. known (Remacle AG, et al.
- the proprotein convertase recognition sequence can be Arg-X-(Arg/Lys)-Arg.
- X indicates any amino acid residue.
- Proprotein convertase recognizes the above amino acid sequence and cleaves the C-terminal side of the C-terminal arginine residue.
- the proprotein convertase is preferably furin, and the furin recognition sequence is the same as the proprotein convertase recognition sequence described above.
- the method for obtaining the polynucleotide encoding the linker or the polynucleotide encoding the proprotein convertase recognition sequence is not particularly limited, and can be obtained by conventional chemical synthesis methods or genetic engineering techniques.
- a polynucleotide encoding a SNARE protein, a polynucleotide encoding an antigen, a polynucleotide encoding a linker, or a polynucleotide encoding a proprotein convertase recognition sequence contained in the nucleic acid construct of the present invention may optionally be It may be codon-optimized for the species to which the construct is to be administered. Information on codons used by various organisms is available from the Codon Usage Database ([www.kazusa.or.jp/codon/]).
- the nucleic acid construct of the present invention is an expression cassette and includes control regions for controlling the expression of a polynucleotide encoding a SNARE protein and a polynucleotide encoding an antigen.
- the SNARE protein-encoding polynucleotide and the antigen-encoding polynucleotide are operably linked to regulatory regions. Examples of regulatory regions include promoters, terminators, enhancers, and the like.
- the expression cassette comprises a promoter linked upstream of the SNARE protein-encoding polynucleotide and the antigen-encoding polynucleotide.
- the nucleic acid construct of the present invention can have restriction enzyme recognition sites at one or both ends.
- the restriction enzyme recognition site can be used to introduce the nucleic acid construct of the present invention into a vector.
- a vector can be cleaved with a restriction enzyme, and the nucleic acid construct of the present invention having restriction enzyme recognition sites at its ends can be added thereto to introduce the nucleic acid construct into the vector.
- the type of vector is not particularly limited, and may be any vector such as a plasmid vector, phage, phagemid, cosmid, or virus vector.
- the vector into which the nucleic acid construct of the invention is to be integrated can be an expression vector, whereas if the nucleic acid construct to be integrated is an expression cassette, it need not be an expression vector.
- the nucleic acid construct of the present invention is an expression cassette containing control regions and incorporated into any vector to construct an expression vector.
- the nucleic acid construct of the present invention is incorporated into an expression vector containing a control region to construct the expression cassette of the present invention on the expression vector.
- the nucleic acid construct of the present invention is a plasmid vector.
- Plasmid vectors include, but are not limited to, plasmid vectors such as pVAX1.
- a plasmid vector generally has a drug resistance gene incorporated within its sequence for the purpose of selectively retaining the plasmid vector during bacterial culture. and the activation and expression of the gene via mammalian promoters, a plasmid vector from which the gene sequence has been removed is more preferable.
- the nucleic acid construct of the present invention is a viral vector.
- Viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, Sendai viral vectors, herpes viral vectors, and the like.
- the nucleic acid construct of the invention is an mRNA construct.
- mRNA construct For example, HiScribe T7 ARCA mRNA Kit (New England Biolabs), T7 mScript TM Standard mRNA Production System (CELLSCRIPT), and HighYield T7 SARCA mRNA using a DNA containing a polynucleotide encoding a SNARE protein and a polynucleotide encoding an antigen as templates.
- the nucleic acid construct of the present invention can be obtained as mRNA by using a commercially available in vitro transcription kit such as Kit (Jena Bioscience).
- a nucleic acid construct comprising a polynucleotide encoding a SNARE protein of the present invention and a polynucleotide encoding an antigen is immunogenic compared to a nucleic acid construct comprising only an antigen-encoding polynucleotide. It is highly potent and can induce or enhance an antigen-specific Th1-type immune response and induce or enhance an antigen-specific cellular immune response. This is because a nucleic acid construct taken up into cells is translated or transcribed and translated, expressed as an antigen protein, transported to intracellular vesicles, and a portion of the antigen binds to major histocompatibility complex (MHC) molecules.
- MHC major histocompatibility complex
- the nucleic acid construct of the present invention expresses the antigen protein as a fusion polypeptide of the SNARE protein and the antigen, thereby targeting the antigen protein to intracellular vesicles. It is presumed that the efficiency of antigen presentation was improved by increasing the probability of association with the MHC molecule. In addition, it has been reported that antigen-containing exosomes enhance antigen-specific Th1-type immune responses in vivo (Qazi KR, et al. Blood. 2009, 113(12): 2673-83 .). Therefore, by expressing the antigen protein as a fusion polypeptide of the SNARE protein and the antigen, it is possible that the antigen protein is targeted to exosomes and immunogenicity is improved.
- the production amount of cytokines such as IFN ⁇ and IL-4 which can serve as indicators for determining whether the immune response is Th1-type or Th2-type, or whether it is a cell-mediated immune response or a humoral immune response.
- cytokines such as IFN ⁇ and IL-4
- a conventionally known method include, for example, ELISA (enzyme-linked immunosorbent assay), ELISPOT (enzyme-linked immunosorbent spot) assay, immunohistochemical staining, in situ hybridization, RT-PCR, microarray, flow cytometry and the like.
- Reagents and kits for measuring cytokine production such as the ELISPOT assay kit (C.T.L.) used in the examples below, are commercially available and may be used for measurement.
- the production amount of each IgG subclass which can be another indicator for determining whether the immune response is Th1 type or Th2 type, or whether it is a cell-mediated immune response or a humoral immune response, It can be measured by a conventionally known method. Such methods include ELISA, immunoturbidimetry, and the like.
- a Th1-type immune response and a cell-mediated immune response can be evaluated using the amount of cytokine production and/or the amount of IgG subclass production as an index. For example, if the production amount of IFN ⁇ or the ratio of IFN ⁇ production to IL-4 (IFN ⁇ /IL-4) increases, it can be evaluated that a Th1-type immune response and a cellular immune response are induced or enhanced.
- the amount of production or IFN ⁇ /IL-4 decreases, it can be evaluated that the Th1-type immune response and cell-mediated immune response are attenuated.
- the production amount of IgG2a and / or the production amount ratio of IgG2a to IgG1 increases, it can be evaluated that the Th1 type immune response and cellular immune response are induced or enhanced, while the production amount of IgG2a And/or if IgG2a/IgG1 is decreased, it can be evaluated that Th1-type immune response and cell-mediated immune response are attenuated.
- the nucleic acid construct of the present invention can be an antigen-specific IFN ⁇ production enhancer, an IgG2a production enhancer, a Th1-type immune response inducer or enhancer, a cell-mediated immune response inducer or enhancer (hereinafter referred to as a cell-mediated immune response inducer or enhancer). agent, etc.), and the nucleic acid construct can be used to produce a cell-mediated immune response-inducing or enhancing agent, or the like.
- the nucleic acid construct of the present invention can be used to enhance antigen-specific IFN ⁇ production, enhance IgG2a production, induce or enhance Th1-type immune response, or induce or enhance cellular immune response. can.
- Non-therapeutic is a concept that does not include medical practice, that is, a concept that does not include methods of surgery, treatment, or diagnosis of humans, more specifically, a doctor or a person who receives instructions from a doctor It is a concept that does not include methods of performing surgery, therapy, or diagnosis.
- the cell-mediated immune response inducer or enhancer, etc. of the present invention per se can be used for antigen-specific IFN ⁇ production enhancement, IgG2a production enhancement, Th1-type immune response induction or enhancement, cellular immune response induction or It can be a drug or quasi-drug for enhancement, or can be a material or preparation used by being blended with the drug or quasi-drug.
- the pharmaceutical can be administered in any dosage form.
- Dosage forms include, for example, oral administration such as tablets, capsules, granules, powders, and syrups, and parenteral administration such as injections, suppositories, inhalants, percutaneous absorption agents, and external preparations. is parenteral administration, more preferably parenteral administration by injection.
- Pharmaceutical formulations of such various dosage forms may contain the nucleic acid construct of the present invention and other pharmaceutically acceptable excipients, binders, fillers, disintegrants, diluents, thickeners, emulsifiers and lubricants.
- agents dispersants, coating agents, surfactants, coating agents, osmotic pressure adjusters, buffers, pH adjusters, preservatives, stabilizers, antioxidants, coloring agents, flavoring agents, corrigents, fragrances, etc. They can be prepared by appropriately combining them.
- the content of the nucleic acid construct of the present invention in the above-mentioned pharmaceuticals varies depending on the target antigen, the subject to be administered, and the route of administration, so it is not particularly limited and can be appropriately selected from a wide range.
- the composition may contain between 0.00001 and 100% by weight of the nucleic acid construct.
- the dosage of the cell-mediated immune response inducer or enhancer, etc. of the present invention may vary according to the subject's species, body weight, sex, age, condition or other factors.
- the dose, route, and interval of administration can be appropriately determined by those skilled in the art.
- the dosage is determined as the amount of the nucleic acid construct of the present invention between 1 ng and 10 mg per adult (60 kg body weight) per day.
- the nucleic acid construct is a viral vector
- the dosage can be, for example, 10 to 1 ⁇ 10 15 viral particles per day for an adult (60 kg body weight).
- the cell-mediated immune response inducer or enhancer of the present invention can be administered to both humans and non-human animals.
- Non-human animals include non-human mammals, such as apes, other primates, mice, rats, horses, cows, pigs, sheep, dogs, cats, hamsters, and companion animals. is mentioned.
- the cell-mediated immune response inducer or enhancer, etc. of the present invention are administered to humans. More preferably, the cell-mediated immune response inducer or enhancer, etc. of the present invention is administered to cancer, autoimmune disease, or allergy patients, or to humans at risk of cancer, autoimmune disease, or allergy.
- nucleic acid construct of the present invention can be a nucleic acid vaccine, and the nucleic acid construct can be used to produce a nucleic acid vaccine.
- nucleic acid constructs of the present invention can be used to induce or enhance antigen-specific Th1-type immune responses and/or to induce or enhance antigen-specific cellular immune responses.
- the use may be administration to a human or non-human animal, or use in a specimen derived therefrom, and may be therapeutic or non-therapeutic.
- the nucleic acid vaccine of the present invention itself serves as a pharmaceutical for inducing or enhancing an antigen-specific Th1-type immune response and/or for inducing or enhancing an antigen-specific cellular immune response. It can be a material or formulation that is used in combination.
- the nucleic acid vaccine is a DNA vaccine.
- DNA vaccines include nucleic acid constructs of the invention that are plasmid vectors.
- plasmid vectors include, but are not limited to, pVAX1 vectors. Among them, a plasmid vector containing no drug resistance gene is preferable from the viewpoint of safety.
- the nucleic acid vaccine is an mRNA vaccine.
- the mRNA vaccine contains the nucleic acid construct of the present invention which is mRNA, and the nucleic acid construct is mRNA treated to add a Cap structure or polyA in order to stabilize the mRNA, improve the translation efficiency, or prevent an excessive immune response. and/or may be an mRNA in which some bases are modified (for example, uridine is replaced with pseudouridine or 1-methylpseudouridine).
- RNA containing the nucleic acid construct of the present invention and containing the sequence of the virus-derived RNA-dependent RNA polymerase (RdRP) complex and its replication origin (5'CSE, 3'CSE), the nucleic acid construct of the present invention and Trans-amplifying RNA may be a mixture of RNA containing the replication origin of the RdRP complex and mRNA containing the sequence of the RdRP complex.
- the mRNA vaccine preferably uses drug delivery such as liposomes or lipid nanoparticles containing lipid as a carrier for stabilizing and delivering mRNA, or polymeric nanoparticles such as PLGA nanoparticles containing high molecular weight polymers. It further comprises a bearing construct, more preferably the mRNA is enclosed in said construct.
- the nucleic acid vaccine is a viral vector vaccine.
- a viral vector vaccine comprises a nucleic acid construct of the invention that is a viral vector.
- viral vectors include, but are not limited to, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, retrovirus vectors, Sendai virus vectors, herpes virus vectors, and the like.
- the nucleic acid vaccine of the present invention may contain a pharmaceutically acceptable carrier as appropriate in addition to the above nucleic acid construct and be formulated in a predetermined form.
- the carrier includes carriers commonly used in the production of vaccines, specifically buffers, emulsifiers, preservatives (e.g., thimerosal), tonicity agents, pH adjusters, thickening agents, Examples include adjuvants or immunostimulators.
- An adjuvant is a substance that enhances an immune response to an antigen when administered together with an antigen. Since the nucleic acid vaccine of the present invention itself can function as an adjuvant, the addition of an adjuvant is not necessarily required.
- the composition may be adjuvant-free.
- the nucleic acid vaccine of the present invention is preferably in liquid form and is appropriately formulated to be compatible with the intended route of administration.
- the route of administration includes oral administration and parenteral administration, and includes, for example, intramuscular, intradermal, subcutaneous, transdermal, intranasal, sublingual, oral, inhalation and the like, preferably intramuscular, intradermal, or Subcutaneous administration.
- Injectable preparations include, for example, liquids, emulsions, water-soluble or hydrophobic suspensions, and dry powders that are dissolved or suspended in a liquid and used.
- the nucleic acid vaccine of the present invention can be administered as dendritic cells introduced with the nucleic acid vaccine of the present invention.
- such administration involves collecting peripheral blood from a living body to be administered, separating dendritic cell progenitor cells, and inducing the differentiation of dendritic cells from the progenitor cells in the presence of appropriate cytokines. can be performed by introducing the nucleic acid vaccine of , causing dendritic cells to present an antigen, and administering the dendritic cells to the administration subject.
- the dendritic cells to be administered are so-called dendritic cell vaccines.
- Dendritic cell vaccines can improve the efficiency of antigen presentation and enhance the ability to induce immunity.
- the content of the nucleic acid construct of the present invention in the nucleic acid vaccine of the present invention varies depending on the target antigen, the subject to be administered, and the route of administration, so it is not particularly limited and can be appropriately selected in a wide range.
- the nucleic acid construct may be included between 0.00001 and 100% by mass of the total nucleic acid vaccine.
- the dosage of the nucleic acid vaccines of the invention may vary according to the subject's species, weight, sex, age, condition or other factors.
- the dose, route, and interval of administration can be appropriately determined by those skilled in the art.
- dosage is determined between 1 ng and 10 mg per dosage unit as the amount of the nucleic acid construct of the present invention.
- the nucleic acid construct is a viral vector
- the dosage can be, by way of example, 10-1 ⁇ 10 15 viral particles per dosage unit.
- the nucleic acid vaccine of the present invention can be administered to both humans and non-human animals. Examples of non-human animals include those similar to those described above.
- the nucleic acid vaccines of the invention are administered to humans. More preferably, the nucleic acid vaccines of the present invention are administered to patients with cancer, autoimmune diseases, or allergies, or to humans at risk of cancer, autoimmune diseases, or allergies.
- the number of times of administration of the nucleic acid vaccine of the present invention may be appropriately set according to the application, and is at least once, but may be twice or more from the viewpoint of efficacy. Further administration is sometimes referred to as boosting and can provide more effective protection against infection or therapeutic effect. A booster interval of at least one week is recommended, with intervals of one to four weeks being preferred.
- nucleic acid vaccines are not pathogenic and are considered to be safer than live and inactivated vaccines.
- nucleic acid encoding the antigen it is possible to deal with a wide variety of antigens, and since it is a nucleic acid, it can be produced rapidly at a low cost.
- the nucleic acid vaccine of the present invention is a cancer vaccine.
- the cancer vaccine comprises a nucleic acid construct comprising a polynucleotide encoding the SNARE protein of the present invention and a polynucleotide encoding a cancer antigen as an antigen.
- the cancer vaccine may be administered to a living body as it is, or may be administered as a dendritic cell vaccine. Such cancer vaccines are believed to induce or enhance cancer antigen-specific cellular immune responses and exert antitumor effects.
- the nucleic acid vaccine of the present invention is an infectious disease vaccine.
- the infectious disease vaccine comprises a nucleic acid construct comprising a polynucleotide encoding a SNARE protein of the present invention and a polynucleotide encoding a viral, bacterial, fungal or protozoal antigen as an antigen.
- the infectious disease vaccine may be directly administered to a living body. It is believed that such infectious disease vaccines can exert preventive or therapeutic effects against infectious diseases by inducing or enhancing cell-mediated immune responses specific to viral antigens, bacterial antigens, fungal antigens, or protozoan antigens.
- HIV human immunodeficiency virus
- HBV hepatitis B virus
- HCV hepatitis C virus
- tuberculosis tuberculosis, etc.
- the nucleic acid vaccine of the present invention is an allergy preventive or therapeutic vaccine, preferably an allergy immunotherapy vaccine.
- the allergy preventive or therapeutic vaccine comprises a nucleic acid construct comprising a polynucleotide encoding the SNARE protein of the present invention and a polynucleotide encoding an allergen as an antigen.
- the allergy preventive or therapeutic vaccine may be directly administered to a living body.
- Such an allergy preventive or therapeutic vaccine induces or enhances allergen-specific Th1-type immune response and cell-mediated immune response, thereby exerting a suppressive effect on allergic response caused by excessive activation of Th2-type immune response. It is possible.
- the nucleic acid vaccine of the present invention is a therapeutic vaccine for autoimmune diseases.
- the autoimmune disease therapeutic vaccine comprises a nucleic acid construct comprising a polynucleotide encoding the SNARE protein of the present invention and a polynucleotide encoding an autoantigen as an antigen.
- the autoimmune disease therapeutic vaccine may be directly administered to a living body.
- Such therapeutic vaccines for autoimmune diseases are thought to be capable of exerting a suppressive effect on autoimmune reactions by inducing immune tolerance against the encoded autoantigens.
- the polynucleotide encoding the SNARE protein and the polynucleotide encoding the antigen are a polynucleotide encoding a linker and/or a polynucleotide encoding a proprotein convertase recognition sequence, preferably a polynucleotide encoding a linker and the nucleic acid construct of [1] or [2] linked via a polynucleotide encoding a proprotein convertase recognition sequence.
- the proprotein convertase recognition sequence is an amino acid sequence consisting of Arg-X-(Arg/Lys)-Arg (X represents any amino acid residue), preferably X-Arg-X-
- the antigen is at least one selected from the group consisting of cancer antigens, autoantigens, viral antigens, bacterial antigens, fungal antigens, protozoan antigens and allergens, preferably cancer antigens, autoantigens, At least one selected from the group consisting of viral antigens, bacterial antigens, fungal antigens, and protozoan antigens, more preferably from the group consisting of cancer antigens, autoantigens, bacterial antigens, fungal antigens, and protozoan antigens
- the nucleic acid construct according to any one of [1] to [5], which is at least one selected.
- the polynucleotide encoding the SNARE protein is preferably selected from the group consisting of polynucleotides consisting of the nucleotide sequences of SEQ ID NOS: 1-9 and 71-75, and polynucleotides having functions equivalent to these.
- the SNARE protein is preferably any selected from the group consisting of VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5 and GOSR1, more preferably VAMP7, GOSR2 and STX10 , STX18, BNIP1, STX7, VTI1A, and GOSR1, more preferably any selected from the group consisting of VAMP7, GOSR2, STX10, and GOSR1, more preferably VAMP7
- the nucleic acid construct according to any one of [1] to [8], which is
- a pharmaceutical composition comprising the nucleic acid construct of any one of [1] to [9].
- a nucleic acid vaccine comprising the nucleic acid construct of any one of [1] to [9] as an active ingredient.
- the nucleic acid vaccine of [11] which induces or enhances an antigen-specific Th1-type immune response.
- the nucleic acid vaccine of [11] which induces or enhances an antigen-specific cellular immune response.
- the nucleic acid vaccine of any one of [11] to [13] which is a cancer vaccine, and wherein the antigen is at least one selected from the group consisting of cancer antigens.
- nucleic acid vaccine any one of [11] to [13], which is an infectious disease vaccine, and wherein the antigen is at least one selected from the group consisting of a viral antigen, a bacterial antigen, a fungal antigen and a protozoan antigen; nucleic acid vaccine.
- nucleic acid construct of any one of [1] to [9] for producing a nucleic acid vaccine.
- nucleic acid vaccine is a cancer vaccine
- the antigen is at least one selected from the group consisting of cancer antigens.
- nucleic acid vaccine is an infectious disease vaccine
- the antigen is at least one selected from the group consisting of viral antigens, bacterial antigens, fungal antigens and protozoan antigens.
- nucleic acid vaccine is an allergy preventive or therapeutic vaccine, and the antigen is at least one selected from the group consisting of allergens.
- nucleic acid vaccine is a vaccine for autoimmune disease treatment, and the antigen is at least one selected from the group consisting of autoantigens.
- nucleic acid vaccine contains preferably 0.00001 to 100% by mass of the nucleic acid construct.
- nucleic acid construct of any one of [1] to [9] for induction or enhancement of antigen-specific Th1-type immune response and/or induction or enhancement of antigen-specific cellular immune response .
- nucleic acid vaccine of any one of [11] to [18] for induction or enhancement of antigen-specific Th1-type immune response and/or induction or enhancement of antigen-specific cellular immune response .
- a method for treating cancer comprising administering an effective amount of the nucleic acid vaccine of [14] to a subject in need thereof.
- a method for preventing or treating an infectious disease which comprises administering an effective amount of the nucleic acid vaccine of [15] to a subject in need thereof.
- a method for preventing or treating allergy which comprises administering an effective amount of the nucleic acid vaccine of [16] to a subject in need thereof.
- a method for treating an autoimmune disease comprising administering an effective amount of the nucleic acid vaccine of [17] to a subject in need thereof.
- the dose of the nucleic acid vaccine is preferably 1 ng to 10 mg of the nucleic acid construct per administration unit, and the nucleic acid vaccine is a viral vector.
- An antigen-specific IFN ⁇ production-enhancing agent comprising the nucleic acid construct of any one of [1] to [9] as an active ingredient.
- An antigen-specific IgG2a production-enhancing agent comprising the nucleic acid construct of any one of [1] to [9] as an active ingredient.
- An antigen-specific Th1-type immune response inducer or enhancer comprising the nucleic acid construct of any one of [1] to [9] as an active ingredient.
- An antigen-specific cellular immune response inducer or enhancer comprising the nucleic acid construct of any one of [1] to [9] as an active ingredient.
- the agent according to any one of [36] to [39] which preferably contains 0.00001 to 100% by mass of the nucleic acid construct.
- nucleic acid construct of any one of [1] to [9] for producing an antigen-specific IFN ⁇ production-enhancing agent.
- nucleic acid construct of any one of [1] to [9] for producing an antigen-specific IgG2a production-enhancing agent.
- nucleic acid construct of any one of [1] to [9] for producing an antigen-specific Th1-type immune response inducer or enhancer.
- nucleic acid construct of any one of [1] to [9] for producing an agent for inducing or enhancing an antigen-specific cellular immune response.
- the use according to any one of [41] to [44], wherein the agent preferably contains 0.00001 to 100% by mass of the nucleic acid construct.
- nucleic acid construct of any one of [1] to [9] for enhancing antigen-specific IFN ⁇ production.
- nucleic acid construct of any one of [1] to [9] for use in enhancing antigen-specific IFN ⁇ production.
- the nucleic acid construct of any one of [1] to [9] for use in inducing or enhancing an antigen-specific cellular immune response.
- a method for enhancing antigen-specific IFN ⁇ production comprising administering an effective amount of the nucleic acid construct of any one of [1] to [9] to a subject in need thereof.
- a method for enhancing antigen-specific IgG2a production comprising administering an effective amount of the nucleic acid construct of any one of [1] to [9] to a subject in need thereof.
- a method of inducing or enhancing an antigen-specific Th1 immune response comprising administering the nucleic acid construct of any one of [1] to [9] to a subject in need thereof in an effective amount.
- a method for inducing or enhancing an antigen-specific cellular immune response comprising administering an effective amount of the nucleic acid construct of any one of [1] to [9] to a subject in need thereof.
- the dose of the nucleic acid construct is preferably 1 ng to 10 mg/60 kg body weight per day, and when the nucleic acid construct is a viral vector, preferably 10 to 1 ⁇ 10 15 viral particles per day. /60 kg body weight, the method of any one of [54] to [57].
- the nucleic acid vaccine is administered orally or parenterally, preferably parenterally.
- the subject in [27], [30], [35] and [54] to [58], the subject is a patient with cancer, an autoimmune disease, or an allergy, or a risk of cancer, an autoimmune disease, or an allergy It is a person with [61] In [31], the subject is a cancer patient or a human at risk of cancer. [62] In [33], the subject is an allergy sufferer or a human with a risk of allergy. [63] In [34], the subject is an autoimmune disease patient or a human at risk of autoimmune disease.
- OVA ovalbumin
- SEQ ID NO: 24 amino acid sequence: SEQ ID NO: 24
- linker amino acid sequence: SEQ ID NO: 19, amino acid sequence: SEQ ID NO: 20
- the amino acid sequence of OVA alone was generated.
- the nucleotide sequence encoding the antigen or fusion polypeptide was codon-optimized and incorporated into plasmid DNA (pVAX1 vector, Thermo Fisher Scientific).
- the nucleotide sequence of OVA integrated into the plasmid DNA is shown in SEQ ID NO:81, and the nucleotide sequences of the fusion polypeptides are shown in SEQ ID NOS:48-68.
- SEQ ID NO: 23 shows the nucleotide sequence of OVA before codon optimization.
- HiScribe T7 ARCA mRNA Kit New England Biolabs
- in vitro mRNA was synthesized by T7 RNA polymerase using the DNA as a template, and the 5' end was capped by ARCA.
- 1.0 ⁇ 10 6 cells of human CD4 + T cells (Lonza) derived from the same donor and 2.5 ⁇ 10 5 cells of transfected dendritic cells were co-cultured for a total of 7 days. Antigen presentation of OVA was performed. Thereafter, 1.0 ⁇ 10 6 CD4 + T cells co-cultured on the ELISPOT plate were co-cultured again with 1.0 ⁇ 10 5 cells of human CD14 + dendritic cells derived from the same donor, and 200 ⁇ g/mL OVA Antigen stimulation was performed by adding protein. After 24 hours, an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect IFN ⁇ -producing CD4 + T cells.
- CTL ELISPOT assay kit
- Th1 immune response can be induced or enhanced by introducing a specific SNARE-OVA fusion protein according to the present invention into antigen-presenting cells such as dendritic cells.
- the Empty (N.T.) group is a control group (Empty) that was not restimulated with the OVA protein.
- Example 2 IgG, IgG1, IgG2a antibody titers VAMP7 was selected from the SNARE proteins that increased IFN ⁇ production in Example 1, and a fusion polypeptide (V7-OVA) was prepared by linking OVA to the C-terminal side of VAMP7 with a linker.
- a plasmid vector (pVAX1 vector, Thermo Fisher Scientific) encoding only the amino acid sequence (SEQ ID NO: 25) or the OVA amino acid sequence (SEQ ID NO: 24) was prepared.
- pVAX1 vector Thermo Fisher Scientific
- SEQ ID NO: 25 amino acid sequence
- SEQ ID NO: 24 OVA amino acid sequence
- an electroporator (NEPA21, Nepagene Co., Ltd.) was used to apply a voltage for gene transfer.
- the animals were euthanized on day 35 and blood was collected. Serum was separated from the collected blood and antibody titer was measured.
- antibody titer measurement 100 ⁇ L/well of a DPBS solution containing 10 ⁇ g/mL OVA (Merck) was added to a 96-well ELISA plate (IWAKI) to immobilize OVA.
- Example 3 ELISPOT Assay An amino acid sequence of a fusion polypeptide (V7-OVA) in which OVA is linked to the C-terminal side of VAMP7 via a linker, or a plasmid vector (pVAX1 vector, Thermo Fisher Scientific) encoding only the amino acid sequence of OVA was prepared. bottom. An empty vector that does not encode an antigen (OVA) was used as a control. After intramuscularly administering 50 ⁇ g of each prepared vector into the thigh muscle of a female BALB/c mouse, an electroporator (NEPA21) was used to apply a voltage for gene transfer.
- V7-OVA fusion polypeptide
- pVAX1 vector Thermo Fisher Scientific
- mice were euthanized on day 35 and spleens were collected.
- the harvested spleen was ground on a 40 ⁇ m cell strainer with the addition of DPBS containing 2% FBS.
- the resulting suspension was centrifuged at 200 xg for 5 minutes, and after removing the supernatant, Pharm Lyse TM solution (BD biosciences) was added and left to stand for 3 minutes to remove red blood cells contained in the suspension. hemolyzed. After centrifuging again at 200 ⁇ g for 5 minutes and removing the supernatant, washing was performed twice with DPBS, and CTL-Test TM Medium (CTL) was added to obtain splenocytes.
- CTL-Test TM Medium CTL-Test TM Medium
- a suspension was obtained. 100 ⁇ L/well of 1.0 ⁇ 10 7 cells/mL splenocytes were seeded on an ELISPOT plate and mixed with 100 ⁇ L of CTL-Test Medium containing OVA protein (Merck) to perform antigen stimulation at a final concentration of 50 ⁇ g/mL. rice field. As a negative control, a group (N.T) to which OVA protein was not added was prepared. After 24 hours, an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect antigen (OVA)-specific IFN ⁇ and IL-4-producing cells. Since the spleen is a secondary lymphoid tissue and its constituent cells, splenocytes, contain abundant T cells, splenocytes were used in this experiment to detect T cells exhibiting antigen-specific immune responses.
- CTL-Test Medium containing OVA protein (Merck) to perform antigen stimulation at a final concentration of 50 ⁇ g/mL. rice field
- VAMP7-OVA V7-OVA
- IL-4 is secreted by Th2 cells
- IFN ⁇ is known to be secreted by Th1 cells or cytotoxic T cells (CD8 + T cells) involved in cell-mediated immunity.
- n 10 in each group
- p ⁇ 0.05 was determined when the Tukey test was performed in each group under non-stimulated conditions (NT) or OVA-stimulated conditions (OVA). was judged to be significant.
- Example 4 IgG, IgG1, IgG2a antibody titer VAMP7, STX10, STX18, or fusion polypeptide (V7-OVA, STX10-OVA, STX18-OVA, GOSR1-OVA) in which OVA is linked to the C-terminal side of GOSR1 via a linker
- a plasmid vector (pVAX1 vector, Thermo Fisher Scientific) encoding only the amino acid sequences (SEQ ID NOS: 25, 27, 28, 41) or the OVA amino acid sequence (SEQ ID NO: 24) was prepared.
- An empty vector that does not encode an antigen (OVA) was used as a control.
- an electroporator (NEPA21) was used to apply a voltage for gene transfer.
- the animals were euthanized on day 35 and blood was collected. Serum was separated from the collected blood and antibody titer was measured.
- antibody titer measurement 100 ⁇ L/well of a DPBS solution containing 10 ⁇ g/mL OVA (Merck) was added to a 96-well ELISA plate (IWAKI) to immobilize OVA.
- Example 5 ELISPOT assay Amino acid sequences (SEQ ID NO: 25, 27, 28, 41), or a plasmid vector (pVAX1 vector, Thermo Fisher Scientific) encoding only the OVA amino acid sequence (SEQ ID NO: 24).
- An empty vector that does not encode an antigen (OVA) was used as a control.
- OVA antigen
- an electroporator NEPA21 was used to apply a voltage for gene transfer. After the above treatments were performed on days 0, 7, and 14 from the start of the experiment, the mice were euthanized on day 35 and spleens were collected.
- the harvested spleen was ground on a 40 ⁇ m cell strainer with the addition of DPBS containing 2% FBS.
- the resulting suspension was centrifuged at 200 xg for 5 minutes, and after removing the supernatant, Pharm Lyse solution (BD biosciences) was added and allowed to stand for 3 minutes to hemolyze red blood cells contained in the suspension. bottom. After centrifuging again at 200 ⁇ g for 5 minutes and removing the supernatant, the cells were washed twice with DPBS, and splenocytes were suspended by adding CTL-Test Medium (CTL). A turbid liquid was obtained.
- CTL-Test Medium CTL-Test Medium
- splenocytes 100 ⁇ L/well of splenocytes of 1.0 ⁇ 10 7 cells were seeded on an ELISPOT plate and mixed with 100 ⁇ L of CTL-Test Medium containing OVA protein (Merck) to perform antigen stimulation at a final concentration of 50 ⁇ g/mL.
- OVA protein Merk
- a group (N.T) to which OVA protein was not added was prepared.
- an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect antigen (OVA)-specific IFN ⁇ and IL-4-producing cells. Since the spleen is a secondary lymphoid tissue and its constituent cells, splenocytes, contain abundant T cells, splenocytes were used in this experiment to detect T cells exhibiting antigen-specific immune responses.
- Example 6 Antibody titer over time The amino acid sequence (SEQ ID NO: 25) of a fusion polypeptide (V7-OVA) in which OVA is linked to the C-terminal side of VAMP7 with a linker, and a proprotein is attached to the C-terminal side of the linker in the fusion polypeptide.
- V7-OVA fusion polypeptide
- the nucleotide sequence of V7-pc-OVA incorporated into the plasmid DNA is shown in SEQ ID NO:69, and the nucleotide sequence of LAMP[OVA] is shown in SEQ ID NO:70.
- An empty vector that does not encode an antigen (OVA) was used as a control.
- an electroporator NEPA21 was used to apply a voltage for gene transfer. The above treatments were performed on days 0, 7 and 14 from the start of the experiment. During the experimental period, blood was collected from the tail vein every week, and the animals were euthanized on the 35th day and blood was collected.
- Serum was separated from the collected blood and antibody titer was measured.
- antibody titer measurement 100 ⁇ L/well of a DPBS solution containing 10 ⁇ g/mL OVA (Merck) was added to a 96-well ELISA plate (IWAKI) to immobilize OVA. The next day, after washing the plate, blocking was performed for 1 hour with 100 ⁇ L/well of DPBS containing 1% BSA. Subsequently, after washing the plate, 100 ⁇ L/well of the separated serum was added while diluting it two-fold stepwise.
- the serum was removed by washing, and 100 ⁇ L/well of 1 ⁇ g/mL anti-Mouse IgG, IgG1, or IgG2a antibody (abcam) was added and allowed to stand for 1 hour.
- 50 ⁇ L/well of TMB solution (abcam) was added to carry out a coloring reaction.
- 50 ⁇ L/well of Stop solution (abcam) was added to stop the coloring reaction, and absorbance was measured (450 nm).
- the antibody titer of each sample was defined as the maximum dilution factor at which the absorbance value was two times or more compared with the absorbance value of the control to which DPBS was added instead of serum.
- VAMP7-OVA and VAMP7-pc-OVA show superior production of antigen-specific IgG antibodies and enhanced antigen-specific Th1-type immune responses, even when compared with LAMP[OVA].
- Example 7 ELISPOT assay Amino acid sequence (SEQ ID NO: 25) of a fusion polypeptide (V7-OVA) in which OVA is linked to the C-terminal side of VAMP7 with a linker, proprotein convertase is added to the C-terminal side of the linker in the fusion polypeptide
- Plasmid vectors encoding only the amino acid sequence (SEQ ID NO: 46) of the fusion polypeptide (V7-pc-OVA) to which the recognition sequence was added or the amino acid sequence (SEQ ID NO: 24) of OVA were prepared. An empty vector that does not encode an antigen (OVA) was used as a control.
- an electroporator (NEPA21) was used to apply a voltage for gene transfer.
- the animals were euthanized on day 35 and spleens were collected.
- the harvested spleen was ground on a 40 ⁇ m cell strainer with the addition of DPBS containing 2% FBS.
- the resulting suspension was centrifuged at 200 xg for 5 minutes, and after removing the supernatant, Pharm Lyse solution (BD biosciences) was added and allowed to stand for 3 minutes to hemolyze red blood cells contained in the suspension. bottom.
- an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect antigen (OVA)-specific IFN ⁇ and IL-4-producing cells. Since the spleen is a secondary lymphoid tissue and its constituent cells, splenocytes, contain abundant T cells, splenocytes were used in this experiment to detect T cells exhibiting antigen-specific immune responses.
- CTL ELISPOT assay kit
- Example 8 IgG, IgG1, IgG2a antibody titer VAMP7 has a proprotein convertase recognition sequence and a cancer antigen, human Wilm Tumor 1 (WT1, amino acid sequence: SEQ ID NO: 84), or an autoantigen, mouse myelin oligodendrocyte, on the C-terminal side of VAMP7.
- WT1 human Wilm Tumor 1
- Amino acid sequences SEQ ID NO : 89, 91
- a plasmid vector encoding only the amino acid sequence of WT1 or MOG 35-55 .
- nucleotide sequence encoding the antigen or fusion polypeptide was codon-optimized and incorporated into plasmid DNA (pVAX1 vector, Thermo Fisher Scientific).
- the nucleotide sequence of WT1 integrated into the plasmid DNA is SEQ ID NO: 83
- nucleotide sequence of MOG 35-55 is SEQ ID NO: 86
- nucleotide sequence of V7-pc-WT1 is SEQ ID NO: 88
- V7-pc-MOG 35-55 is shown in SEQ ID NO:90.
- nucleotide sequence of WT1 before codon optimization is shown in SEQ ID NO: 82
- nucleotide sequence of MOG 35-55 before codon optimization is shown in SEQ ID NO: 85.
- MOG 35-55 is a peptide in which the 35-55 residue portion of mouse MOG is repeated seven times.
- an empty vector that does not encode an antigen was used as a control.
- an electroporator was used to apply a voltage for gene transfer.
- WT1-specific IgG was observed in both WT1 alone and VAMP7-pc-WT1 (V7-pc-WT1) groups, although no significant difference was observed compared to the group administered with empty vector. An increase in antibody titer was observed. On the other hand, WT1-specific IgG1 and IgG2a antibody titers were elevated in V7-pc-WT1 compared to Empty and WT1 alone, although no significant difference was observed.
- IgG2a/IgG1 the ratio of WT1-specific IgG1 and IgG2a antibody titers in each individual was calculated, no change was observed between WT1 alone and V7-pc-WT1.
- MOG-specific IgG antibody titer was measured, there was no change in both MOG 35-55 alone and VAMP7-pc-MOG 35-55 (V7-pc-MOG 35-55 ) groups compared to Empty. I was not able to admit.
- MOG-specific IgG1 and IgG2a antibody titers were elevated in V7-pc-MOG 35-55 compared to Empty and MOG 35-55 alone, and only the IgG1 antibody titer was significantly changed.
- Example 9 ELISPOT assay Fusion polypeptides (V7-pc-WT1, V7-pc-MOG 35-55 ) in which the proprotein convertase recognition sequence and human WT1 or mouse MOG 35-55 are linked to the C-terminal side of VAMP7 with a linker
- a plasmid vector (pVAX1 vector, Thermo Fisher Scientific) encoding only the amino acid sequences of WT1 or MOG 35-55 (SEQ ID NOS: 84 and 87) was prepared.
- pVAX1 vector Thermo Fisher Scientific
- an electroporator (NEPA21) was used to apply a voltage for gene transfer.
- the animals were euthanized on day 28 and spleens were collected.
- the harvested spleen was ground on a 40 ⁇ m cell strainer with the addition of DPBS containing 2% FBS.
- the resulting suspension was centrifuged at 200 xg for 5 minutes, and after removing the supernatant, Pharm Lyse solution (BD biosciences) was added and allowed to stand for 3 minutes to hemolyze red blood cells contained in the suspension. bottom.
- CTL-Test Medium CTL-Test Medium
- 1.0 ⁇ 10 7 cells of splenocytes are seeded on an ELISPOT plate at 100 ⁇ L/well and mixed with 100 ⁇ L of CTL-Test Medium supplemented with human WT1 peptide mix (Miltenyi Biotec) or mouse MOG 35-55 peptide (Merck).
- antigen stimulation was performed at a final concentration of 1.2 nmol/mL or 5 ⁇ g/mL.
- a group (NT) to which no antigen was added was prepared. After 24 hours, an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect antigen (WT1 or MOG 35-55 )-specific IFN ⁇ and IL-4-producing cells. bottom. Since the spleen is a secondary lymphoid tissue and its constituent cells, splenocytes, contain abundant T cells, splenocytes were used in this experiment to detect T cells exhibiting antigen-specific immune responses.
- CTL ELISPOT assay kit
- V7-pc-WT1 significantly increased the number of T cells secreting IFN ⁇ in a WT1-specific manner.
- V7-pc-MOG 35-55 significantly increased the number of T cells secreting IFN ⁇ specifically for MOG 35-55 compared to MOG 35-55 alone.
- WT1 peptide mix stimulation conditions WT1
- NT no stimulation
- WT1 No change was observed in any of the groups in the IL-4 ratio calculated for each individual under each condition.
- the number of T cells secreting MOG 35-55-specific IL-4 was also measured under non-stimulated conditions (NT) and MOG 35-55 peptide-stimulated conditions (MOG 35-55 ). Although a significant inter-group difference was observed in N.C. No change was observed in all groups in the IL-4 ratio calculated for each individual under each condition of T and MOG 35-55 . Furthermore, when the ratio of the number of T cells producing IFN ⁇ and IL-4 in each individual, IFN ⁇ /IL-4, was calculated, compared with each antigen alone at each antigen stimulation, V7-pc-WT1 or V7-pc-MOG 35 -55 had a significant increase in IFN ⁇ /IL-4.
- Example 10 ELISPOT assay Amino acid sequence (SEQ ID NO: 25) of a fusion polypeptide (V7-OVA) in which OVA is linked to the C-terminal side of VAMP7 with a linker, proprotein convertase is added to the C-terminal side of the linker in the fusion polypeptide Amino acid sequence (SEQ ID NO: 46) of fusion polypeptide (V7-pc-OVA) with recognition sequence added, fusion polypeptide (LAMP [OVA] ) or the amino acid sequence of OVA (SEQ ID NO: 24). An empty vector that does not encode an antigen (OVA) was used as a control.
- an electroporator (NEPA21) was used to apply a voltage for gene transfer.
- Animals were euthanized and spleens harvested 7 days after the above treatment.
- the harvested spleen was ground on a 40 ⁇ m cell strainer with the addition of DPBS containing 2% FBS.
- the resulting suspension was centrifuged at 200 xg for 5 minutes, and after removing the supernatant, Pharm Lyse solution (BD biosciences) was added and allowed to stand for 3 minutes to hemolyze red blood cells contained in the suspension. bottom.
- an ELISPOT assay was performed using an ELISPOT assay kit (CTL) according to the attached protocol to detect antigen (OVA)-specific IFN ⁇ and IL-4-producing cells. Since the spleen is a secondary lymphoid tissue and its constituent cells, splenocytes, contain abundant T cells, splenocytes were used in this experiment to detect T cells exhibiting antigen-specific immune responses.
- CTL ELISPOT assay kit
- VAMP7-pc-OVA showed a significant increase in the number of T cells that secrete IFN ⁇ specifically in OVA, even just one week after vector administration. confirmed.
- the number of T cells secreting OVA-specific IL-4 was significantly different between groups under non-stimulated conditions (NT) and OVA-stimulated conditions (OVA).
- NT non-stimulated conditions
- OVA-stimulated conditions OVA
- VAMP7-pc-OVA can selectively induce antigen-specific Th1-type immunity and cell-mediated immunity without triggering an antigen-specific Th2-type immune response from a relatively early period of 1 week. Furthermore, it has been shown that there is a superior immunity-inducing effect compared to conventional techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
(特許文献2)特表2008-500014号公報
(非特許文献1)Chen AC, et al. J Immunother Cancer. 2020; 8(1): e000258.
(非特許文献2)Jahn R, Scheller RH. Nat Rev Mol Cell Biol. 2006; 7(9): 631-643.
(非特許文献3)Hong W. Biochim Biophys Acta. 2005; 1744(2): 120-144.
1)VAMP7、GOSR2、STX10、STX18、BNIP1、STX7、VTI1A、STX16、STX5、GOSR1、STX8、STX12、VAMP8、及びSEC22Bからなる群より選択されるいずれかのSNAREタンパク質をコードするポリヌクレオチドと、抗原をコードするポリヌクレオチドとを含む、核酸構築物。
2)1)の核酸構築物を有効成分とする抗原特異的Th1型免疫応答誘導又は増強剤。
3)1)の核酸構築物を有効成分とする抗原特異的細胞性免疫応答誘導又は増強剤。
4)1)の核酸構築物を有効成分とする核酸ワクチン。
また、当該「遺伝子」は特定のヌクレオチド配列で表される「遺伝子」だけではなく、これらの同族体(すなわち、ホモログもしくはオーソログ)、遺伝子多型等の変異体、及び誘導体をコードする核酸が包含される。
本明細書中に開示される遺伝子の名称及びGene IDは、NCBI([www.ncbi.nlm.nih.gov/])に記載のあるOfficial Symbol及びGene IDに従う。
本発明の核酸構築物によれば、抗原特異的なTh1型免疫応答を誘導又は増強でき、また、抗原特異的な細胞性免疫応答を誘導又は増強することができる。斯かる核酸構築物は、核酸ワクチンとして有用である。
(a)配列番号10のアミノ酸配列からなるポリペプチド;
(b)配列番号10のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド;
(c)配列番号10のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド;
(d)配列番号1のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド。
配列番号1のヌクレオチド配列からなるVAMP7遺伝子のスプライシングバリアントとしては、NCBIのRefSeq(Reference Sequence)にNM_001185183.2又はNM_001145149.3として登録され、それぞれ、NP_001172112.1又はNP_001138621.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号11のアミノ酸配列からなるポリペプチド;
(b)配列番号11のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド;
(c)配列番号11のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド;
(d)配列番号2のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド。
配列番号2のヌクレオチド配列からなるGOSR2遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_054022.4、NM_004287.5、NM_001353114.2、NM_001012511.3、NM_001363851.2、NM_001330252.2、NM_001353116.2、NM_001353115.2、又はNM_001321134.2として登録され、それぞれ、NP_473363.1、NP_004278.2、NP_001340043.1、NP_001012529.1、NP_001350780.1、NP_001317181.1、NP_001340045.1、NP_001340044.1、又はNP_001308063.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号12のアミノ酸配列からなるポリペプチド;
(b)配列番号12のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(c)配列番号12のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(d)配列番号3のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド。
配列番号3のヌクレオチド配列からなるSTX10遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001271610.2、NM_1271609.2、又はNM_001271611.2として登録され、それぞれ、NP_001258539.1、NP_001258538.1、又はNP_001258540.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号13のアミノ酸配列からなるポリペプチド;
(b)配列番号13のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(c)配列番号13のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(d)配列番号4のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド。
配列番号4のヌクレオチド配列からなるSTX18遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001346281.2、NM_001346282.2、又はNM_001346300.2として登録され、それぞれ、NP_001333210.1、NP_001333211.1、又はNP_001333229.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号14のアミノ酸配列からなるポリペプチド;
(b)配列番号14のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(c)配列番号14のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(d)配列番号5のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド。
配列番号5のヌクレオチド配列からなるBNIP1遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_013980.3、NM_001205.3、又はNM_013978.3として登録され、それぞれ、NP_053583.2、NP_001196.2、又はNP_053581.2として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号15のアミノ酸配列からなるポリペプチド;
(b)配列番号15のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(c)配列番号15のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(d)配列番号6のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド。
配列番号6のヌクレオチド配列からなるSTX7遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001326578.2、NM_001326579.2、又はNM_001326580.2として登録され、それぞれ、NP_001313507.1、NP_001313508.1、又はNP_001313509.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号16のアミノ酸配列からなるポリペプチド;
(b)配列番号16のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(c)配列番号16のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(d)配列番号7のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド。
配列番号7のヌクレオチド配列からなるVTI1A遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_145206.4、NM_001365711.1、NM_001365710.2、NM_001365712.1、NM_001365713.1、NM_001365714.1、又はNM_001318205.2として登録され、それぞれ、NP_660207.2、NP_001352640.1、NP_001352639.1、NP_001352641.1、NP_001352642.1、NP_001352643.1、又はNP_001305134.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号17のアミノ酸配列からなるポリペプチド;
(b)配列番号17のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(c)配列番号17のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(d)配列番号8のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド。
配列番号8のヌクレオチド配列からなるSTX16遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001134772.3、NM_1134773.3、NM_003763.6、又はNM_001204868.2として登録され、それぞれ、NP_001128244.1、NP_001128245.1、NP_003754.2、又はNP_001191797.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号18のアミノ酸配列からなるポリペプチド;
(b)配列番号18のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド;
(c)配列番号18のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド;
(d)配列番号9のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド。
配列番号9のヌクレオチド配列からなるSTX5遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001244666.3、又はNM_001330294.2として登録され、それぞれ、NP_001231595.1、又はNP_001317223.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号76のアミノ酸配列からなるポリペプチド;
(b)配列番号76のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(c)配列番号76のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(d)配列番号71のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントにコードされるアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(d)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド。
配列番号71のヌクレオチド配列からなるGOSR1遺伝子のスプライシングバリアントとしては、NCBIのRefSeqにNM_001007025.2又はNM_001007024.2として登録され、それぞれ、NP_001007026.1又はNP_001007025.1として登録されるタンパク質をコードするバリアントが挙げられる。
(a)配列番号77のアミノ酸配列からなるポリペプチド;
(b)配列番号77のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(c)配列番号77のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(c)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド。
(a)配列番号78のアミノ酸配列からなるポリペプチド;
(b)配列番号78のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド;
(c)配列番号78のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(c)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド。
(a)配列番号79のアミノ酸配列からなるポリペプチド;
(b)配列番号79のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(c)配列番号79のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(c)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド。
(a)配列番号80のアミノ酸配列からなるポリペプチド;
(b)配列番号80のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(c)配列番号80のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド;
(e)上記(a)~(c)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド。
(f)配列番号1のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号1のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号1のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号1のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号1のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号10のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号10のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号10のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、後期エンドソーム又はリソソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号2のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号2のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号2のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号2のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号2のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号11のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号11のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号11のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体-ゴルジ体中間区間又はゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号3のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号3のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号3のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号3のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号3のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号12のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号12のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号12のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号4のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号4のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号4のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号4のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号4のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号13のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号13のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号13のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号5のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号5のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号5のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号5のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号5のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号14のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号14のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号14のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号6のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号6のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号6のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号6のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号6のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号15のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号15のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号15のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号7のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号7のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号7のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号7のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号7のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号16のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号16のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号16のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号8のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号8のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号8のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号8のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号8のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号17のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号17のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号17のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、トランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号9のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号9のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号9のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号9のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号9のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号18のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号18のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号18のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号71のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号71のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号71のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(i)配列番号71のヌクレオチド配列からなるポリヌクレオチドのスプライシングバリアントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号71のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号76のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号76のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号76のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号72のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号72のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号72のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号72のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(h)及び(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号77のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号77のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号77のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号73のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号73のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号73のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号73のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(h)及び(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号78のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号78のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号78のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、ゴルジ体、初期エンドソーム又はリサイクリングエンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号74のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号74のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号74のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号74のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(h)及び(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号79のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号79のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号79のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、リソソーム、初期エンドソーム又は後期エンドソーム)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
(f)配列番号75のヌクレオチド配列からなるポリヌクレオチド;
(g)配列番号75のヌクレオチド配列と少なくとも80%の同一性を有するヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(h)配列番号75のヌクレオチド配列に対して1個又は数個のヌクレオチドが欠失、置換、付加、又は挿入されたヌクレオチド配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(j)配列番号75のヌクレオチド配列からなるポリヌクレオチドの相補鎖に対してストリンジェントな条件下でハイブリダイズし、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(k)上記(f)~(h)及び(j)のいずれかのポリヌクレオチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチドをコードするポリヌクレオチド;
(l)配列番号80のアミノ酸配列からなるポリペプチドをコードするポリヌクレオチド;
(m)配列番号80のアミノ酸配列と少なくとも80%の同一性を有するアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(n)配列番号80のアミノ酸配列に対して1個又は数個のアミノ酸が欠失、置換、付加、又は挿入されたアミノ酸配列からなり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド;
(o)上記(l)~(n)のいずれかのポリペプチドのフラグメントであり、かつ膜貫通ドメインを有し、細胞内小胞(例えば、小胞体、小胞体-ゴルジ体中間区間、ゴルジ体、シスゴルジネットワーク又はトランスゴルジネットワーク)又はエクソソームに局在することができるポリペプチド、をコードするポリヌクレオチド。
人為的に免疫応答を誘発する標的となる自己抗原としては、アルツハイマー型認知症では、Amyloid β、Tau proteinなどのタンパク質又はそれに由来するペプチドが挙げられ、パーキンソン病では、α sinucleinなどのタンパク質又はそれに由来するペプチドが挙げられ、動脈硬化症では、Cholesterol ester transfer protein、ApoB-100、Proprotein convertase subtilisin/kexin type 9、Heat shock protein 60などのタンパク質又はそれに由来するペプチドが挙げられ、高血圧症では、Type-1 angiotensin II receptor、Alpha 1D-Adrenergic Receptorなどのタンパク質又はそれに由来するペプチドが挙げられ、2型糖尿病では、Dipeptidyl peptidase 4などのタンパク質又はそれに由来するペプチドが挙げられ、肥満症では、Glucagon-like peptide-1、Ghrelin、Peptide YYなどのタンパク質又はそれに由来するペプチドが挙げられ、骨粗しょう症では、receptor activator of NF-kappaB ligand(RANKL)などのタンパク質又はそれに由来するペプチドが挙げられる。
細菌抗原は、細菌を構成するタンパク質又はそれに由来するペプチドを意味する。細菌抗原としては、特に限定されないが、百日咳菌、ジフテリア菌、大腸菌、インフルエンザ菌、ヘリコバクター、髄膜炎菌、緑膿菌、肺炎球菌、A群連鎖球菌、B群連鎖球菌、黄色ブドウ球菌、破傷風菌、レジオネラ菌、結核菌、マイコプラズマなどの細菌の構成タンパク質又はそれに由来するペプチドが挙げられる。
真菌抗原としては、真菌やその胞子を構成するタンパク質又はそれに由来するペプチドを意味する。真菌抗原としては、アスペルギルス属真菌(例えばAspergillus fumigatus、Aspergillus flavus、Aspergillus terreus、Aspergillus nidulans、Aspergillus niger、Aspergillus ustus等)、ブラストミセス属真菌(例えば、Blastomyces dermatitidis等)、カンジダ属真菌(例えばCandida albicans等)、コクシジオイデス属真菌(例えばCoccidiodes immitis等)、クリプトコッカス属真菌(例えばCryptococcus neoformans、Cryptococcus gattii等)、ヒストプラズマ属真菌(例えばHistoplasma capsulatum等)、パラコクシジオイデス属真菌(例えばParacoccidioides brasiliensis等)、スポロトリクス属真菌(例えばSporothrix schenckii等)などの真菌やその胞子の構成タンパク質又はそれに由来するペプチドが挙げられる。
原生動物抗原としては、原生動物を構成するタンパク質又はそれに由来するペプチドを意味する。原生動物抗原としては、マラリア原虫、リーシュマニア、クリプトスポリジウム、ガンビアトリパノソーマ、ローデシアトリパノソーマ、クルーズトリパノソーマ、トリコモナス、トキソプラズマ、バベシア、赤痢アメーバ、ジアルジアなどの原生動物の構成タンパク質又はそれに由来するペプチドが挙げられる。
このうち、感染症抗原として、細菌抗原、真菌抗原、又は原生動物抗原が好ましい。
また、免疫応答がTh1型であるかTh2型であるか、あるいは細胞性免疫応答であるか液性免疫応答であるかを判定するための別の指標となり得るIgGのサブクラス別の産生量は、従来公知の方法で測定することができる。そのような方法としては、ELISA、免疫比濁法などが挙げられる。
Th1型免疫応答及び細胞性免疫応答は、サイトカインの産生量及び/又はIgGサブクラスの産生量を指標として、評価することができる。例えば、IFNγの産生量又はIL-4に対するIFNγの産生量比率(IFNγ/IL-4)が増加すれば、Th1型免疫応答及び細胞性免疫応答が誘導又は増強されたと評価でき、一方、IFNγの産生量又はIFNγ/IL-4が低下すれば、Th1型免疫応答及び細胞性免疫応答が減弱したと評価できる。あるいは、IgG2aの産生量及び/又はIgG1に対するIgG2aの産生量比率(IgG2a/IgG1)が増加すれば、Th1型免疫応答及び細胞性免疫応答が誘導又は増強されたと評価でき、一方、IgG2aの産生量及び/又はIgG2a/IgG1が低下すれば、Th1型免疫応答及び細胞性免疫応答が減弱したと評価できる。
また、本発明の核酸構築物は、抗原特異的なIFNγ産生を増強するため、IgG2a産生を増強するため、Th1型免疫応答を誘導又は増強するため、細胞性免疫応答を誘導又は増強するために使用できる。ここで、当該使用は、ヒト若しくは非ヒト動物への投与、又はそれらに由来する検体における使用であり得、また治療的使用であっても非治療的使用であってもよい。尚、「非治療的」とは、医療行為を含まない概念、すなわち人間を手術、治療又は診断する方法を含まない概念、より具体的には医師又は医師の指示を受けた者が人間に対して手術、治療又は診断を実施する方法を含まない概念である。
このような種々の剤型の医薬製剤は、本発明の核酸構築物と他の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、希釈剤、増粘剤、乳化剤、滑沢剤、分散剤、被膜剤、界面活性剤、被膜剤、浸透圧調整剤、緩衝剤、pH調整剤、防腐剤、安定剤、酸化防止剤、着色剤、嬌味剤、矯臭剤、香料等を適宜組み合わせて調製することができる。
さらに、本発明の核酸構築物は、抗原特異的なTh1型免疫応答を誘導もしくは増強するため及び/又は抗原特異的な細胞性免疫応答を誘導もしくは増強するために使用できる。ここで、当該使用は、ヒト若しくは非ヒト動物への投与、又はそれらに由来する検体における使用であり得、また治療的使用であっても非治療的使用であってもよい。
ここで、担体としては、ワクチンの製造に通常用いられる担体が挙げられ、具体的には、緩衝剤、乳化剤、保存剤(例えば、チメロサール)、等張化剤、pH調整剤、粘稠剤、アジュバント若しくは免疫刺激剤等が例示される。アジュバントとは、抗原と共に投与することで、当該抗原に対する免疫応答を増強させる物質であるが、本発明の核酸ワクチンは、自身がアジュバントとして機能し得ることから、アジュバントの添加は必ずしも必要とせず、アジュバントを含有しない組成物としてもよい。
〔2〕前記SNAREタンパク質をコードするポリヌクレオチドの下流に前記抗原をコードするポリヌクレオチドが連結されている、〔1〕記載の核酸構築物。
〔3〕前記SNAREタンパク質をコードするポリヌクレオチド及び前記抗原をコードするポリヌクレオチドが、リンカーをコードするポリヌクレオチド及び/又はプロタンパク質転換酵素認識配列をコードするポリヌクレオチド、好ましくはリンカーをコードするポリヌクレオチド及びプロタンパク質転換酵素認識配列をコードするポリヌクレオチドを介して連結されている、〔1〕又は〔2〕記載の核酸構築物。
〔4〕前記該プロタンパク質転換酵素認識配列が、Arg-X-(Arg/Lys)-Argからなるアミノ酸配列(Xは任意のアミノ酸残基を示す)であり、好ましくはX-Arg-X-(Arg/Lys)-Argからなるアミノ酸配列(Xは任意のアミノ酸残基を示す)であり、より好ましくは配列番号22で示されるアミノ酸配列である、〔3〕記載の核酸構築物。
〔5〕プラスミドベクター、mRNA、又はウイルスベクターである、〔1〕~〔4〕のいずれか1項記載の核酸構築物。
〔6〕前記抗原が、がん抗原、自己抗原、ウイルス抗原、細菌抗原、真菌抗原、原生動物抗原及びアレルゲンからなる群より選択される少なくとも1種であり、好ましくはがん抗原、自己抗原、ウイルス抗原、細菌抗原、真菌抗原、及び原生動物抗原からなる群より選択される少なくとも1種であり、より好ましくはがん抗原、自己抗原、細菌抗原、真菌抗原、及び原生動物抗原からなる群より選択される少なくとも1種である、〔1〕~〔5〕のいずれか1項記載の核酸構築物。
〔7〕前記SNAREタンパク質が、好ましくは哺乳動物のSNAREタンパク質であり、より好ましくはヒトSNAREタンパク質である、〔1〕~〔6〕のいずれか1項記載の核酸構築物。
〔8〕前記SNAREタンパク質をコードするポリヌクレオチドが、好ましくは配列番号1~9及び71~75のヌクレオチド配列からなるポリヌクレオチド及びこれらと同等の機能を有するポリヌクレオチドからなる群より選択されるいずれかのポリヌクレオチドであり、より好ましくは配列番号1~9及び71~75のいずれかのヌクレオチド配列からなるポリヌクレオチドである、〔1〕~〔7〕のいずれか1項記載の核酸構築物。
〔9〕前記SNAREタンパク質が、好ましくはVAMP7、GOSR2、STX10、STX18、BNIP1、STX7、VTI1A、STX16、STX5、及びGOSR1からなる群より選択されるいずれかであり、より好ましくはVAMP7、GOSR2、STX10、STX18、BNIP1、STX7、VTI1A、及びGOSR1からなる群より選択されるいずれかであり、さらに好ましくはVAMP7、GOSR2、STX10、及びGOSR1からなる群より選択されるいずれかであり、さらに好ましくはVAMP7である、〔1〕~〔8〕のいずれか1項記載の核酸構築物。
〔11〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を有効成分とする核酸ワクチン。
〔12〕抗原特異的Th1型免疫応答を誘導又は増強するものである、〔11〕記載の核酸ワクチン。
〔13〕抗原特異的細胞性免疫応答を誘導又は増強するものである、〔11〕記載の核酸ワクチン。
〔14〕がんワクチンであり、前記抗原ががん抗原からなる群より選択される少なくとも1種である、〔11〕~〔13〕のいずれか1項記載の核酸ワクチン。
〔15〕感染症ワクチンであり、前記抗原がウイルス抗原、細菌抗原、真菌抗原及び原生動物抗原からなる群より選択される少なくとも1種である、〔11〕~〔13〕のいずれか1項記載の核酸ワクチン。
〔16〕アレルギー予防又は治療用ワクチンであり、前記抗原がアレルゲンからなる群より選択される少なくとも1種である、〔11〕~〔13〕のいずれか1項記載の核酸ワクチン。
〔17〕自己免疫疾患治療用ワクチンであり、前記抗原が自己抗原からなる群より選択される少なくとも1種である、〔11〕~〔13〕のいずれか1項記載の核酸ワクチン。
〔18〕前記核酸ワクチンが、前記核酸構築物を、好ましくは0.00001~100質量%含有する、〔11〕~〔17〕のいずれか1項記載の核酸ワクチン。
〔20〕前記核酸ワクチンががんワクチンであり、前記抗原ががん抗原からなる群より選択される少なくとも1種である、〔19〕記載の使用。
〔21〕前記核酸ワクチンが感染症ワクチンであり、前記抗原がウイルス抗原、細菌抗原、真菌抗原及び原生動物抗原からなる群より選択される少なくとも1種である、〔19〕記載の使用。
〔22〕前記核酸ワクチンがアレルギー予防又は治療用ワクチンであり、前記抗原がアレルゲンからなる群より選択される少なくとも1種である、〔19〕記載の使用。
〔23〕前記核酸ワクチンが自己免疫疾患治療用ワクチンであり、前記抗原が自己抗原からなる群より選択される少なくとも1種である、〔19〕記載の使用。
〔24〕前記核酸ワクチンが、前記核酸構築物を、好ましくは0.00001~100質量%含有する、〔19〕~〔23〕のいずれか1項記載の使用。
〔26〕抗原特異的Th1型免疫応答の誘導もしくは増強及び/又は抗原特異的細胞性免疫応答の誘導もしくは増強に使用するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物。
〔27〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を、それを必要とする対象に有効量で投与する、抗原特異的Th1型免疫応答の誘導もしくは増強及び/又は抗原特異的細胞性免疫応答の誘導もしくは増強方法。
〔29〕抗原特異的Th1型免疫応答の誘導もしくは増強及び/又は抗原特異的細胞性免疫応答の誘導もしくは増強に使用するための、〔11〕~〔18〕のいずれか1項記載の核酸ワクチン。
〔30〕〔11〕~〔18〕のいずれか1項記載の核酸ワクチンを、それを必要とする対象に有効量で投与する、抗原特異的Th1型免疫応答の誘導もしくは増強及び/又は抗原特異的細胞性免疫応答の誘導もしくは増強方法。
〔31〕〔14〕記載の核酸ワクチンを、それを必要とする対象に有効量で投与する、がんの治療方法。
〔32〕〔15〕記載の核酸ワクチンを、それを必要とする対象に有効量で投与する、感染症の予防又は治療方法。
〔33〕〔16〕記載の核酸ワクチンを、それを必要とする対象に有効量で投与する、アレルギーの予防又は治療方法。
〔34〕〔17〕記載の核酸ワクチンを、それを必要とする対象に有効量で投与する、自己免疫疾患治療方法。
〔35〕前記核酸ワクチンの投与量が、該核酸ワクチンがDNAワクチン又はmRNAワクチンの場合に、1投与単位あたり、前記核酸構築物の量として、好ましくは1ng~10mgであり、該核酸ワクチンがウイルスベクターワクチンの場合に、1投与単位あたり、好ましくは10~1×1015ウイルス粒子である、〔30〕~〔34〕のいずれか1項記載の方法。
〔37〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を有効成分とする抗原特異的IgG2a産生増強剤。
〔38〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を有効成分とする抗原特異的Th1型免疫応答誘導又は増強剤。
〔39〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を有効成分とする抗原特異的細胞性免疫応答誘導又は増強剤。
〔40〕前記剤が、前記核酸構築物を、好ましくは0.00001~100質量%含有する、〔36〕~〔39〕のいずれか1項記載の剤。
〔42〕抗原特異的IgG2a産生増強剤を製造するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔43〕抗原特異的Th1型免疫応答誘導又は増強剤を製造するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔44〕抗原特異的細胞性免疫応答誘導又は増強剤を製造するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔45〕前記剤が、前記核酸構築物を、好ましくは0.00001~100質量%含有する、〔41〕~〔44〕のいずれか1項記載の使用。
〔47〕抗原特異的IgG2a産生増強のための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔48〕抗原特異的Th1型免疫応答誘導又は増強のための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔49〕抗原特異的細胞性免疫応答誘導又は増強のための、〔1〕~〔9〕のいずれか1項記載の核酸構築物の使用。
〔51〕抗原特異的IgG2a産生増強に使用するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物。
〔52〕抗原特異的Th1型免疫応答誘導又は増強に使用するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物。
〔53〕抗原特異的細胞性免疫応答誘導又は増強に使用するための、〔1〕~〔9〕のいずれか1項記載の核酸構築物。
〔55〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を、それを必要とする対象に有効量で投与する、抗原特異的IgG2a産生増強方法。
〔56〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を、それを必要とする対象に有効量で投与する、抗原特異的Th1型免疫応答誘導又は増強方法。
〔57〕〔1〕~〔9〕のいずれか1項記載の核酸構築物を、それを必要とする対象に有効量で投与する、抗原特異的細胞性免疫応答誘導又は増強方法。
〔58〕前記核酸構築物の投与量が、1日あたり、好ましくは1ng~10mg/60kg体重であり、該核酸構築物がウイルスベクターの場合に、1日あたり、好ましくは10~1×1015ウイルス粒子/60kg体重である、〔54〕~〔57〕のいずれか1項記載の方法。
〔60〕〔27〕、〔30〕、〔35〕及び〔54〕~〔58〕において、対象はがん、自己免疫疾患、もしくはアレルギーの患者、又はがん、自己免疫疾患、もしくはアレルギーの恐れのあるヒトである。
〔61〕〔31〕において、対象はがん患者又はがんの恐れのあるヒトである。
〔62〕〔33〕において、対象はアレルギー患者又はアレルギーの恐れのあるヒトである。
〔63〕〔34〕において、対象は自己免疫疾患患者又は自己免疫疾患の恐れのあるヒトである。
21種類の各ヒトSNAREタンパク質のC末端側にアレルゲンであるオボアルブミン(OVA、アミノ酸配列:配列番号24)をリンカー(ヌクレオチド配列:配列番号19、アミノ酸配列:配列番号20)で連結した融合ポリペプチドのアミノ酸配列(配列番号25~45)又はOVAのみのアミノ酸配列をコードしたmRNAを作製した。この時、抗原又は融合ポリペプチドをコードするヌクレオチド配列はコドン最適化を施したうえでプラスミドDNA(pVAX1 vector、Thermo Fisher Scientific)へ組み込んだ。プラスミドDNAに組み込んだOVAのヌクレオチド配列を配列番号81に、融合ポリペプチドのヌクレオチド配列を配列番号48~68に示す。また、OVAのコドン最適化前のヌクレオチド配列を配列番号23に示す。mRNAの作製にはHiScribe T7 ARCA mRNA Kit(New England Biolabs)を用いた。具体的には、各配列を組み込んだプラスミドDNAについて制限酵素を用いて線形化した後、当該DNAを鋳型としてT7 RNA polymeraseによるin vitro mRNA合成並びにARCAによる5’末端のCap化を行った。続いて、DNaseを添加することで鋳型として用いたDNAを分解した後、Poly(A)PolymeraseによるポリA鎖の付加を行った。得られたmRNAをRNeasy kit(QIAGEN)を用いて精製し、以降の操作に用いた。精製したmRNAをTransIT-mRNA Transfection Reagent(Mirus Bio)を用いて添付のプロトコルに従い、成熟したヒトCD14+樹状細胞(Lonza)にトランスフェクションした。コントロールとして、mRNAを含まないトランスフェクション試薬のみを樹状細胞に添加した。トランスフェクションの翌日から、同ドナー由来のヒトCD4+T細胞(Lonza)1.0×106cellsとトランスフェクションした樹状細胞2.5×105cellsについて共培養を計7日間行い、mRNA由来OVAの抗原提示を行った。その後、ELISPOTプレート上で共培養したCD4+T細胞1.0×106cellsを同ドナー由来のヒトCD14+樹状細胞1.0×105cellsと再度共培養すると共に、200μg/mLのOVAタンパク質を添加して抗原刺激を行った。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、IFNγを産生するCD4+T細胞を検出した。
実施例1でIFNγの産生を増加させたSNAREタンパク質からVAMP7を選択し、VAMP7のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA)のアミノ酸配列(配列番号25)、又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vector(pVAX1 vector、Thermo Fisher Scientific)を作製した。コントロールとしては、抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21、ネッパジーン株式会社)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、35日目に安楽死させ血液を採取した。採取した血液から血清を分離し、抗体価測定を行った。抗体価測定では、10μg/mLのOVA(Merck)を溶解したDPBS溶液を96 well ELISA plate(IWAKI)に対し100μL/well添加し、OVAの固相化を行った。翌日、plateを洗浄した後、100μL/wellの1%BSA含有DPBSでブロッキングを1時間行った。続いて、plateを洗浄した後、分離した血清を段階的に2倍希釈しながら100μL/well添加した。2時間後、血清を洗浄して除き、1μg/mLのanti-Mouse IgG、IgG1、又はIgG2a抗体(abcam)を100μL/well添加し1時間静置した。その後、TMB溶液(abcam)を50μL/well添加し発色反応を行った。10分後、Stop solution(abcam)を50μL/well添加し、発色反応を停止させ、吸光度測定(450nm)を行った。この時、血清の代わりにDPBSを添加したコントロールの吸光度と比較して、2倍以上の吸光度値が測定された最大希釈倍率の値を各サンプルの抗体価と定義した。
VAMP7のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA)のアミノ酸配列、又はOVAのアミノ配列のみをコードしたplasmid vector(pVAX1 vector、Thermo Fisher Scientific)を作製した。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、35日目に安楽死させ脾臓を採取した。採取した脾臓を、2%FBS含有DPBSを添加しながら40μmセルストレーナー上ですりつぶした。得られた懸濁液について200×gで5分間遠心を行い、上清を除いた後、Pharm LyseTM solution(BD biosciences)を添加し3分間静置することで懸濁液に含まれる赤血球を溶血した。再度、200×gで5分間遠心を行い、上清を除いた後、DPBSで2回洗浄を行い、CTL-TestTM Medium(C.T.L.)を添加することで脾細胞(splenocyte)懸濁液を得た。1.0×107cells/mLのsplenocyteをELISPOTプレート上に100μL/well播種し、OVAタンパク質(Merck)を添加したCTL-Test Medium 100μLと混合することで終濃度50μg/mLで抗原刺激を行った。ネガティブコントロールとしてはOVAタンパク質を添加していない群(N.T)を用意した。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、抗原(OVA)特異的にIFNγ、IL-4を産生する細胞を検出した。脾臓は2次リンパ組織であり、その構成細胞であるSplenocyteはT細胞を豊富に含有することから、抗原特異的な免疫応答を示すT細胞を検出するため本実験ではSplenocyteを用いた。
VAMP7、STX10、STX18、若しくはGOSR1のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA、STX10-OVA、STX18-OVA、GOSR1-OVA)のアミノ酸配列(配列番号25、27、28、41)、又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vector(pVAX1 vector、Thermo Fisher Scientific)を作製した。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、35日目に安楽死させ血液を採取した。採取した血液から血清を分離し、抗体価測定を行った。抗体価測定では、10μg/mLのOVA(Merck)を溶解したDPBS溶液を96 well ELISA plate(IWAKI)に対し100μL/well添加し、OVAの固相化を行った。翌日、plateを洗浄した後、100μL/wellの1%BSA含有DPBSで1時間ブロッキングを行った。続いて、plateを洗浄した後、分離した血清を段階的に2倍希釈しながら100μL/well添加した。2時間後、血清を洗浄して除き、1μg/mLのanti-Mouse IgG、IgG1、又はIgG2a抗体(abcam)を100μL/well添加し1時間静置した。その後、TMB溶液(abcam)を50μL/well添加し発色反応を行った。10分後、Stop solution(abcam)を50μL/well添加し、発色反応を停止させ、吸光度測定(450nm)を行った。この時、血清の代わりにDPBSを添加したコントロールの吸光度と比較して、2倍以上の吸光度値が測定された最大希釈倍率の値を各サンプルの抗体価と定義した。
VAMP7、STX10、STX18、若しくはGOSR1のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA、STX10-OVA、STX18-OVA、GOSR1-OVA)のアミノ酸配列(配列番号25、27、28、41)、又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vector(pVAX1 vector、Thermo Fisher Scientific)を作製した。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、35日目に安楽死させ脾臓を採取した。採取した脾臓を、2%FBS含有DPBSを添加しながら40μmセルストレーナー上ですりつぶした。得られた懸濁液について200×gで5分間遠心を行い、上清を除いた後、Pharm Lyse solution(BD biosciences)を添加し3分間静置することで懸濁液に含まれる赤血球を溶血した。再度、200×gで5分間遠心を行い、上清を除いた後、DPBSで2回洗浄を行い、CTL-Test Medium(C.T.L.)を添加することで脾細胞(splenocyte)懸濁液を得た。1.0×107cellsのsplenocyteをELISPOTプレート上に100μL/well播種し、OVAタンパク質(Merck)を添加したCTL-Test Medium 100μLと混合することで終濃度50μg/mLで抗原刺激を行った。ネガティブコントロールとしてはOVAタンパク質を添加していない群(N.T)を用意した。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、抗原(OVA)特異的にIFNγ、IL-4を産生する細胞を検出した。脾臓は2次リンパ組織であり、その構成細胞であるSplenocyteはT細胞を豊富に含有することから、抗原特異的な免疫応答を示すT細胞を検出するため本実験ではSplenocyteを用いた。
VAMP7のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA)のアミノ酸配列(配列番号25)、該融合ポリペプチド中のリンカーのC末端側にプロタンパク質転換酵素認識配列(ヌクレオチド配列:配列番号21、アミノ酸配列:配列番号22)を付加した融合ポリペプチド(V7-pc-OVA)のアミノ酸配列(配列番号46)、リソソーム結合タンパク質LAMP(特許文献1)内にOVAのアミノ酸配列を挿入した融合ポリペプチド(LAMP[OVA])のアミノ酸配列(配列番号47)又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vectorを作製した。プラスミドDNAに組み込んだV7-pc-OVAのヌクレオチド配列を配列番号69に、LAMP[OVA]のヌクレオチド配列を配列番号70に示す。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った。実験期間中、1週間毎に尾静脈から採血を行い、35日目に安楽死させ血液を採取した。採取した血液から血清を分離し、抗体価測定を行った。抗体価測定では、10μg/mLのOVA(Merck)を溶解したDPBS溶液を96 well ELISA plate(IWAKI)に対し100μL/well添加し、OVAの固相化を行った。翌日、plateを洗浄した後、100μL/wellの1%BSA含有DPBSでブロッキングを1時間行った。続いて、plateを洗浄した後、分離した血清を段階的に2倍希釈しながら100μL/well添加した。2時間後、血清を洗浄して除き、1μg/mLのanti-Mouse IgG、IgG1、又はIgG2a抗体(abcam)を100μL/well添加し1時間静置した。その後、TMB溶液(abcam)を50μL/well添加し発色反応を行った。10分後、Stop solution(abcam)を50μL/well添加し、発色反応を停止させ、吸光度測定(450nm)を行った。この時、血清の代わりにDPBSを添加したコントロールの吸光度と比較して、2倍以上の吸光度値が測定された最大希釈倍率の値を各サンプルの抗体価と定義した。
VAMP7のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA)のアミノ酸配列(配列番号25)、該融合ポリペプチド中のリンカーのC末端側にプロタンパク質転換酵素認識配列を付加した融合ポリペプチド(V7-pc-OVA)のアミノ酸配列(配列番号46)、又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vectorを作製した。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、35日目に安楽死させ脾臓を採取した。採取した脾臓を、2%FBS含有DPBSを添加しながら40μmセルストレーナー上ですりつぶした。得られた懸濁液について200×gで5分間遠心を行い、上清を除いた後、Pharm Lyse solution(BD biosciences)を添加し3分間静置することで懸濁液に含まれる赤血球を溶血した。再度、200×gで5分間遠心を行い、上清を除いた後、DPBSで2回洗浄を行い、CTL-Test Medium(C.T.L.)を添加することで脾細胞(splenocyte)懸濁液を得た。1.0×107cellsのsplenocyteをELISPOTプレート上に100μL/well播種し、OVAタンパク質(Merck)を添加したCTL-Tes Medium 100μLと混合することで終濃度50μg/mLで抗原刺激を行った。ネガティブコントロールとしてはOVAタンパク質を添加していない群(N.T)を用意した。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、抗原(OVA)特異的にIFNγ、IL-4を産生する細胞を検出した。脾臓は2次リンパ組織であり、その構成細胞であるSplenocyteはT細胞を豊富に含有することから、抗原特異的な免疫応答を示すT細胞を検出するため本実験ではSplenocyteを用いた。
VAMP7のC末端側にプロタンパク質転換酵素認識配列とがん抗原であるヒトWilm Tumor 1(WT1、アミノ酸配列:配列番号84)若しくは自己抗原であるマウスmyelin oligodendrocyte glycoproteinペプチドの繰り返し配列(MOG35-55、アミノ酸配列:配列番号87)をリンカーで連結した融合ポリペプチド(V7-pc-WT1、V7-pc-MOG35-55)のアミノ酸配列(配列番号89、91)、又はWT1若しくはMOG35-55のアミノ酸配列のみをコードしたplasmid vectorを作製した。この時、抗原又は融合ポリペプチドをコードするヌクレオチド配列はコドン最適化を施したうえでプラスミドDNA(pVAX1 vector、Thermo Fisher Scientific)へ組み込んだ。プラスミドDNAに組み込んだWT1のヌクレオチド配列を配列番号83に、MOG35-55のヌクレオチド配列を配列番号86に、V7-pc-WT1のヌクレオチド配列を配列番号88に、V7-pc-MOG35-55のヌクレオチド配列を配列番号90に示す。また、WT1のコドン最適化前のヌクレオチド配列を配列番号82に、MOG35-55のコドン最適化前のヌクレオチド配列を配列番号85に示す。ここで、MOG35-55とは、マウスMOGの35~55残基部分を7回繰り返したペプチドである。コントロールとしては、抗原(WT1又はMOG35-55)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、28日目に安楽死させ血液を採取した。採取した血液から血清を分離し、抗体価測定を行った。抗体価測定では、1μg/mLのヒトWT1(Cusabio Technology LLC)又は10μg/mLのマウスMOG35-55 peptide(Merck)を溶解したDPBS溶液を96 well ELISA plate(Iwaki)に対し100μL/well添加し、各抗原の固相化を行った。翌日、plateを洗浄した後、100μL/wellの1%BSA含有DPBSでブロッキングを1時間行った。続いて、plateを洗浄した後、分離した血清を段階的に2倍希釈しながら100μL/well添加した。2時間後、血清を洗浄して除き、1μg/mLのanti-Mouse IgG、IgG1、又はIgG2a抗体(abcam)を100μL/well添加し1時間静置した。その後、TMB溶液(abcam)を50μL/well添加し発色反応を行った。10分後、Stop solution(abcam)を50μL/well添加し、発色反応を停止させ、吸光度測定(450nm)を行った。この時、血清の代わりにDPBSを添加したコントロールの吸光度と比較して、2倍以上の吸光度値が測定された最大希釈倍率の値を各サンプルの抗体価と定義した。
VAMP7のC末端側にプロタンパク質転換酵素認識配列とヒトWT1若しくはマウスMOG35-55をリンカーで連結した融合ポリペプチド(V7-pc-WT1、V7-pc-MOG35-55)のアミノ酸配列(配列番号89、91)、又はWT1若しくはMOG35-55のアミノ酸配列(配列番号84、87)のみをコードしたplasmid vector(pVAX1 vector、Thermo Fisher Scientific)を作製した。コントロールとしては、抗原(WT1又はMOG35-55)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置を実験開始から0、7、14日目に行った後、28日目に安楽死させ脾臓を採取した。採取した脾臓を、2%FBS含有DPBSを添加しながら40μmセルストレーナー上ですりつぶした。得られた懸濁液について200×gで5分間遠心を行い、上清を除いた後、Pharm Lyse solution(BD biosciences)を添加し3分間静置することで懸濁液に含まれる赤血球を溶血した。再度、200×gで5分間遠心を行い、上清を除いた後、DPBSで2回洗浄を行い、CTL-Test Medium(C.T.L.)を添加することで脾細胞(splenocyte)懸濁液を得た。1.0×107cellsのsplenocyteをELISPOTプレート上に100μL/well播種し、ヒトWT1 peptide mix(Miltenyi Biotec)、又はマウスMOG35-55 peptide(Merck)を添加したCTL-Test Medium 100μLと混合することで各終濃度が1.2nmol/mL、又は5μg/mLで抗原刺激を行った。ネガティブコントロールとしては抗原を添加していない群(N.T)を用意した。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、抗原(WT1又はMOG35-55)特異的にIFNγ、IL-4を産生する細胞を検出した。脾臓は2次リンパ組織であり、その構成細胞であるSplenocyteはT細胞を豊富に含有することから、抗原特異的な免疫応答を示すT細胞を検出するため本実験ではSplenocyteを用いた。
VAMP7のC末端側にOVAをリンカーで連結した融合ポリペプチド(V7-OVA)のアミノ酸配列(配列番号25)、該融合ポリペプチド中のリンカーのC末端側にプロタンパク質転換酵素認識配列を付加した融合ポリペプチド(V7-pc-OVA)のアミノ酸配列(配列番号46)、リソソーム結合タンパク質LAMP(特許文献1)内にOVAのアミノ酸配列を挿入した融合ポリペプチド(LAMP[OVA])のアミノ酸配列(配列番号47)、又はOVAのアミノ酸配列(配列番号24)のみをコードしたplasmid vectorを作製した。コントロールとしては抗原(OVA)をコードしていないEmpty vectorを用いた。作製したそれぞれのvector50μgを雌のBALB/cマウスの大腿筋内部へ筋肉内投与した後、エレクトロポレーター(NEPA21)を用いて電圧を負荷し遺伝子導入を行った。上記処置から7日目に安楽死させ脾臓を採取した。採取した脾臓を、2%FBS含有DPBSを添加しながら40μmセルストレーナー上ですりつぶした。得られた懸濁液について200×gで5分間遠心を行い、上清を除いた後、Pharm Lyse solution(BD biosciences)を添加し3分間静置することで懸濁液に含まれる赤血球を溶血した。再度、200×gで5分間遠心を行い、上清を除いた後、DPBSで2回洗浄を行い、CTL-Test Medium(C.T.L.)を添加することで脾細胞(splenocyte)懸濁液を得た。1.0×107cellsのsplenocyteをELISPOTプレート上に100μL/well播種し、OVAタンパク質(Merck)を添加したCTL-Test Medium 100μLと混合することで終濃度50μg/mLで抗原刺激を行った。ネガティブコントロールとしてはOVAタンパク質を添加していない群(N.T)を用意した。24時間後、ELISPOTアッセイキット(C.T.L.)を用い、添付のプロトコルに従ってELISPOTアッセイを行い、抗原(OVA)特異的にIFNγ、IL-4を産生する細胞を検出した。脾臓は2次リンパ組織であり、その構成細胞であるSplenocyteはT細胞を豊富に含有することから、抗原特異的な免疫応答を示すT細胞を検出するため本実験ではSplenocyteを用いた。
Claims (13)
- VAMP7、GOSR2、STX10、STX18、BNIP1、STX7、VTI1A、STX16、STX5、GOSR1、STX8、STX12、VAMP8、及びSEC22Bからなる群より選択されるいずれかのSNAREタンパク質をコードするポリヌクレオチドと、抗原をコードするポリヌクレオチドとを含む、核酸構築物。
- 前記SNAREタンパク質をコードするポリヌクレオチドの下流に前記抗原をコードするポリヌクレオチドが連結されている、請求項1記載の核酸構築物。
- 前記SNAREタンパク質をコードするポリヌクレオチド及び前記抗原をコードするポリヌクレオチドが、リンカーをコードするポリヌクレオチド及び/又はプロタンパク質転換酵素認識配列をコードするポリヌクレオチドを介して連結されている、請求項1又は2記載の核酸構築物。
- プラスミドベクター、mRNA、又はウイルスベクターである、請求項1~3のいずれか1項記載の核酸構築物。
- 前記抗原ががん抗原、自己抗原、細菌抗原、真菌抗原、及び原生動物抗原からなる群より選択される少なくとも1種である、請求項1~4のいずれか1項記載の核酸構築物。
- 請求項1~5のいずれか1項記載の核酸構築物を有効成分とする抗原特異的Th1型免疫応答誘導又は増強剤。
- 請求項1~5のいずれか1項記載の核酸構築物を有効成分とする抗原特異的細胞性免疫応答誘導又は増強剤。
- 請求項1~5のいずれか1項記載の核酸構築物を有効成分とする核酸ワクチン。
- 抗原特異的Th1型免疫応答を誘導又は増強するものである、請求項8記載の核酸ワクチン。
- 抗原特異的細胞性免疫応答を誘導又は増強するものである、請求項8記載の核酸ワクチン。
- がんワクチンであり、前記抗原ががん抗原からなる群より選択される少なくとも1種である、請求項8~10のいずれか1項記載の核酸ワクチン。
- 自己免疫疾患治療用ワクチンであり、前記抗原が自己抗原からなる群より選択される少なくとも1種である、請求項8~10のいずれか1項記載の核酸ワクチン。
- 経口又は非経口により投与される、請求項8~12のいずれか1項記載の核酸ワクチン。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022322527A AU2022322527A1 (en) | 2021-08-06 | 2022-08-05 | Nucleic acid structure utilizing snare |
EP22853203.2A EP4382605A1 (en) | 2021-08-06 | 2022-08-05 | Nucleic acid structure utilizing snare |
CA3228426A CA3228426A1 (en) | 2021-08-06 | 2022-08-05 | Nucleic acid structure utilizing snare |
CN202280055113.4A CN117795081A (zh) | 2021-08-06 | 2022-08-05 | 利用snare的核酸构建体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-130022 | 2021-08-06 | ||
JP2021130022 | 2021-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023013785A1 true WO2023013785A1 (ja) | 2023-02-09 |
Family
ID=85154500
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/030202 WO2023013787A1 (ja) | 2021-08-06 | 2022-08-05 | Snareを活用した核酸構築物 |
PCT/JP2022/030201 WO2023013786A1 (ja) | 2021-08-06 | 2022-08-05 | Snareを活用した核酸構築物 |
PCT/JP2022/030200 WO2023013785A1 (ja) | 2021-08-06 | 2022-08-05 | Snareを活用した核酸構築物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/030202 WO2023013787A1 (ja) | 2021-08-06 | 2022-08-05 | Snareを活用した核酸構築物 |
PCT/JP2022/030201 WO2023013786A1 (ja) | 2021-08-06 | 2022-08-05 | Snareを活用した核酸構築物 |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP4382606A1 (ja) |
JP (4) | JP2023024408A (ja) |
CN (3) | CN117795080A (ja) |
AU (3) | AU2022322527A1 (ja) |
CA (3) | CA3228433A1 (ja) |
WO (3) | WO2023013787A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500014A (ja) | 2003-10-14 | 2008-01-10 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン | 組換えワクチンおよびその使用 |
JP2017079742A (ja) | 2016-11-16 | 2017-05-18 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルギー治療のための核酸 |
JP2019528042A (ja) * | 2016-07-08 | 2019-10-10 | ザ チルドレンズ メディカル センター コーポレーション | 新規ボツリヌスニューロトキシンおよびその誘導体 |
JP2021500871A (ja) * | 2017-09-29 | 2021-01-14 | ザ チルドレンズ メディカル センター コーポレーション | ニューロトキシン様トキシンおよびそれらの使用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2861240T1 (sl) * | 2012-06-15 | 2021-04-30 | Immunomic Therapeutics, Inc. | Nukleinske kisline za zdravljenje alergij |
-
2022
- 2022-08-05 WO PCT/JP2022/030202 patent/WO2023013787A1/ja active Application Filing
- 2022-08-05 AU AU2022322527A patent/AU2022322527A1/en active Pending
- 2022-08-05 CN CN202280055098.3A patent/CN117795080A/zh active Pending
- 2022-08-05 WO PCT/JP2022/030201 patent/WO2023013786A1/ja active Application Filing
- 2022-08-05 CN CN202280055113.4A patent/CN117795081A/zh active Pending
- 2022-08-05 EP EP22853204.0A patent/EP4382606A1/en active Pending
- 2022-08-05 JP JP2022125893A patent/JP2023024408A/ja active Pending
- 2022-08-05 EP EP22853203.2A patent/EP4382605A1/en active Pending
- 2022-08-05 CA CA3228433A patent/CA3228433A1/en active Pending
- 2022-08-05 JP JP2022125895A patent/JP2023024410A/ja active Pending
- 2022-08-05 CA CA3228426A patent/CA3228426A1/en active Pending
- 2022-08-05 AU AU2022321126A patent/AU2022321126A1/en active Pending
- 2022-08-05 EP EP22853205.7A patent/EP4382607A1/en active Pending
- 2022-08-05 WO PCT/JP2022/030200 patent/WO2023013785A1/ja active Application Filing
- 2022-08-05 CN CN202280055080.3A patent/CN117795079A/zh active Pending
- 2022-08-05 CA CA3228430A patent/CA3228430A1/en active Pending
- 2022-08-05 JP JP2022125894A patent/JP7326557B2/ja active Active
- 2022-08-05 AU AU2022321271A patent/AU2022321271A1/en active Pending
-
2023
- 2023-07-27 JP JP2023122616A patent/JP2023145617A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500014A (ja) | 2003-10-14 | 2008-01-10 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン | 組換えワクチンおよびその使用 |
JP2019528042A (ja) * | 2016-07-08 | 2019-10-10 | ザ チルドレンズ メディカル センター コーポレーション | 新規ボツリヌスニューロトキシンおよびその誘導体 |
JP2017079742A (ja) | 2016-11-16 | 2017-05-18 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルギー治療のための核酸 |
JP2021500871A (ja) * | 2017-09-29 | 2021-01-14 | ザ チルドレンズ メディカル センター コーポレーション | ニューロトキシン様トキシンおよびそれらの使用 |
Non-Patent Citations (12)
Title |
---|
CHEN AC ET AL., J IMMUNOTHER CANCER, vol. 8, no. 1, 2020, pages e000258 |
HASHIMOTO-GOTOH ET AL., GENE, vol. 152, 1995, pages 271 - 276 |
HIROKAWA ET AL., BIOINFORMATICS, vol. 14, no. 4, 1998, pages 378 - 379 |
HONG W., BIOCHIM BIOPHYS ACTA, vol. 1744, no. 2, 2005, pages 120 - 144 |
HORTON ET AL., GENE, vol. 77, 1989, pages 61 - 68 |
JAHN RSCHELLER RH, NAT REV MOL CELL BIOL., vol. 7, no. 9, 2006, pages 631 - 643 |
KROUGH ET AL., J MOL BIOL., vol. 305, no. 3, 2001, pages 567 - 580 |
KUNKEL, T. A., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 |
QAZI KR ET AL., BLOOD, vol. 113, no. 12, 2009, pages 2673 - 83 |
REMACLE AG ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 30, 2008, pages 20897 - 20906 |
SCIENCE, vol. 227, 1985, pages 1435 - 1441 |
YUMIKO NAGAI; SATOSHI TADOKORO; HIROKI SAKIYAMA; NAOHIDE HIRASHIMA;: "Effects of synaptotagmin 2 on membrane fusion between liposomes that contain SNAREs involved in exocytosis in mast cells", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1808, no. 10, 6 July 2011 (2011-07-06), AMSTERDAM, NL , pages 2435 - 2439, XP028265602, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2011.07.003 * |
Also Published As
Publication number | Publication date |
---|---|
CN117795080A (zh) | 2024-03-29 |
CA3228433A1 (en) | 2023-02-09 |
JP2023145617A (ja) | 2023-10-11 |
CN117795081A (zh) | 2024-03-29 |
WO2023013787A1 (ja) | 2023-02-09 |
AU2022321271A1 (en) | 2024-02-29 |
AU2022322527A1 (en) | 2024-02-29 |
JP2023024409A (ja) | 2023-02-16 |
EP4382606A1 (en) | 2024-06-12 |
EP4382607A1 (en) | 2024-06-12 |
CN117795079A (zh) | 2024-03-29 |
AU2022321126A1 (en) | 2024-02-29 |
JP7326557B2 (ja) | 2023-08-15 |
JP2023024408A (ja) | 2023-02-16 |
CA3228426A1 (en) | 2023-02-09 |
CA3228430A1 (en) | 2023-02-09 |
JP2023024410A (ja) | 2023-02-16 |
EP4382605A1 (en) | 2024-06-12 |
WO2023013786A1 (ja) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109069605B (zh) | 新免疫原性CD1d结合肽 | |
US10350284B1 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
EA023897B1 (ru) | Композиции, которые индуцируют хелперное действие т-клеток | |
CA3145228A1 (en) | African swine fever vaccine | |
CN106061509B (zh) | 编码端粒酶的dna疫苗 | |
CN115246874A (zh) | 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用 | |
US20060251667A1 (en) | Recombinant nucleic acid useful for inducing protective immune response against allergens | |
KR20230005265A (ko) | Sars-cov-2에 대한 백신 및 이의 제조 | |
WO2023013785A1 (ja) | Snareを活用した核酸構築物 | |
US20240189404A1 (en) | Immunogenic peptides with extended oxidoreductase motifs | |
JP7000314B2 (ja) | 免疫療法における使用のためのポリエピトープ構築物 | |
CA3220605A1 (en) | Methods of treating or preventing autoimmune diseases | |
CN115569189A (zh) | 治疗hpv感染的疫苗组合 | |
CN118340875A (zh) | 一种水痘-带状疱疹病毒的mRNA疫苗及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22853203 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280055113.4 Country of ref document: CN Ref document number: 3228426 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022322527 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022322527 Country of ref document: AU Date of ref document: 20220805 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022853203 Country of ref document: EP Effective date: 20240306 |